Does The Microbiome Hold The Key To Treating Parkinson’s, Autism & Other Diseases? CalTech Microbiologist Dr. Sarkis Mazmazian on The Gut-Brain Axis

This week, I am joined by microbiologist Dr. Sarkis Mazmanian, the Luis B. and Nelly Soux Professor at Caltech, to discuss the microbiome's connection to human health—especially the gut-brain axis. Dr. Mazmanian discusses his research evolution from infectious diseases to the microbiome’s role in neurodevelopment and neurodegeneration, as well as how gut microbes influence neurological health, behavior, and conditions like Parkinson's, autism, and depression. He highlights the human gut microbe symbiosis, early-life microbial exposure's influence, and the adult microbiome's malleability. We explore microbiome-based therapeutics' potential, challenges in translating animal models to humans, personalized medicine's future, the microbiome's impact on drug efficacy, gut bacteria's influence on behaviors and cravings, and the importance of a healthy gut diet. Please enjoy! Show notes + MORE Watch on YouTube Newsletter Sign-Up Today’s Sponsors: AG1: Get a FREE 1-year supply of Vitamin D3+K2 AND 5 free AG1 Travel Packs 👉drinkAG1.com/richroll InsideTracker: Use code RICHROLL at checkout and enjoy 10% OFF the InsideTracker Subscription and any plan 👉insidetracker.com/richroll On: 10% OFF your first order of high-performance shoes and apparel w/ code RICHROLL10👉on.com/richroll Roka: Unlock 20% OFF sunglasses & eyewear with code RICHROLL 👉roka.com/richroll Go Brewing: Use the code Rich Roll for 15% OFF my favorite non-alcoholic brews 👉gobrewing.com Squarespace: Use the offer code RichRoll to save 10% off your first purchase of a website or domain 👉Squarespace.com/RichRoll Learn more about your ad choices. Visit podcastchoices.com/adchoices

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Rich Roll?

  Eating well rarely falls apart because of one big failure. It's the daily question that wears you down. Like, what am I actually gonna make tonight? What's in the fridge? And it's exactly why we built the Plant Power Meal Planner. It's a personalized, plant-based meal planning program that matches you with recipes based on your taste, your allergies, your cooking skills, and how much time you actually have. You build, through this program, a balanced, nutrient-dense plan for your entire household in a few minutes. Then it generates a grocery list for you with one click that plugs right into our delivery partners. All the recipes in the program are built by dietitians with culinary training. Plus, you get your own food coach to help you problem-solve along the way.

• 0:44Rich Roll?

  It's kind of an amazing thing. For listeners of the show, all you special people, we're offering an exclusive $20 off an annual subscription right now. To get it, go to meals.richroll.com, take your quick personalization quiz, and enter promo code RICHROLL20 at checkout.

• 1:05Speaker 01

  Is the microbiome involved? In Parkinson's. We took mice that were genetically predisposed to developing symptoms of Parkinson's, and we just cleared out their microbiome. All their symptoms went away.

• 1:18Rich Roll?

  My guest today is Dr. Sarkis Mazmanian, one of the world's leading microbiome research scientists.

• 1:26Speaker 01

  What we've shown is that the microbiome affects your development. There are dozens and dozens, hundreds of molecules in our brain that come from our gut bacteria and nowhere else. I think we've essentially set ourselves up to fail. As we've disassociated ourselves from microbes, the rates of allergic and autoimmune diseases have increased.

• 1:46Rich Roll?

  Dr. Mazmanian is a professor of microbiology at Caltech, where his cutting-edge lab focuses on how gut bacteria impact immune and nervous system function.

• 1:58Speaker 01

  The vast majority of drugs that are FDA-approved work in less than 50% of their patient population. And as we sit here today in 2024, it's still very, very hard to correct a person's genetics, but we certainly can change their microbiome.

• 2:12Rich Roll?

  In this conversation, we discuss the gut-brain axis, the relationship between the microbiome and the immune system. We discuss its impact on mood, our stress response, social behavior, neurodivergence, Parkinson's, and more. Plus, how the microbiome is shaping the future of therapeutics, and plenty more. You're in for a treat because in addition to being a brilliant mind, Dr. Mazmanian is also just a fantastic communicator. So, take notes and enjoy.

• 2:49Rich Roll?

  Sarkis, thank you for coming to do this. Very excited to talk to you. The microbiome has been a recurring theme on this show. It's a subject of endless fascination. And I think just to begin, if you could share a little bit about your area, your field of study, and your domain expertise, and what led you into this field?

• 3:13Speaker 01

  Thanks for having me, Rich. Wonderful to talk about our work. I remember exactly where I was sitting, where I read a one-page article about all these bacteria that live in our intestines, and we know nothing about them. And this is 23 years ago or so. And I thought to myself, that's what I want to do. That's what I want to study, is something that is really just this uncharted territory, but clearly has to be important for biology and maybe health.

• 3:40Speaker 01

  Did a postdoc at Harvard where I developed both the knowledge and the experimental systems to study the microbiome. And then, in terms of my area of research, initially worked on how microbes impact the immune system. Felt like that was a natural transition for our research because, again, the vast majority, all of us actually, probably grew up thinking that our immune system is equipped to fight off microbes. That's what it does, and certainly it does that. But what we discovered, and now many other people have shown as well, is that our microbiome educates our immune system. Our immune system functions well because of bacteria. It's just different bacteria than the ones That make us sick.

• 4:23Speaker 01

  And showed in a number of studies that microbiome effects on the immune system essentially made animals healthier, made them more resistant to autoimmune or allergic reactions. And really, I think that resonated with the scientific community. Because it was just, first, heresy to think microbes were good for us. But the data were strong and again, highly reproducible across many, many labs across the world. And then just more recently, got more bold and asked, can we test whether or not the microbiome affects other organ systems in the body? Does it go just beyond the immune system?

• 5:07Speaker 01

  And about 13, 14 years ago, started working on how microbes affect the nervous system. And that's really the bulk of our work now is to show. And what we've shown is that the microbiome affects neurodevelopment. Think of autism or anxiety and depression or other neuropsychiatric symptoms. And then neurodegeneration, mostly in Parkinson's disease models. Again, happy to talk about all that research.

• 5:32Rich Roll?

  Yeah, we're definitely going to do that. I want to go deep on the gut-brain access as well as the relationship between the microbiome and the immune system. But let's start with some real basics, like what is the microbiome? You described the human being as this scaffold that we are but hosts to trillions of microbes. But how do you define it?

• 6:01Speaker 01

  Our microbiome is the collective genomes, the collective DNA, the coding material of all the organisms that live in or on us. And so microbiota refers to the cells, refers to the actual microbes themselves. And they take many different forms. The vast majority are bacteria, but they include archaea, fungi, viruses, protozoans. And most of these organisms live in our gastrointestinal tract, the majority of which are lower gastrointestinal tract, in our colons.

• 6:34Speaker 01

  But our skin, upper airways, vaginal cavity, oral cavity are just teeming with microbes. In fact, every, you know, environmentally exposed surfaces, surface of our body, except the deep alveoli of our lungs are just covered with bacteria.

• 6:48Rich Roll?

  Mm hmm.

• 6:49Speaker 01

  Right? They're not inside of us, at least that's what the most current literature and data suggests, that they're not living in our blood or our internal tissues. They can get there, that's when disease happens. But because they're living on the environmentally exposed surfaces, we are their scaffold. We are the home to all these different communities. And as you said, trillions, up to 100 trillion bacterial cells, again, which really dominate on a numerical basis. And, you know, fun fact that I think maybe many people are not aware of is that we have more bacterial cells in our bodies than human cells.

• 7:22Rich Roll?

  Right.

• 7:22Speaker 01

  You know, maybe three to five times as many bacteria than our own cells. And I think that just really drives the point home of really the magnitude of our interactions with bacteria.

• 7:31Rich Roll?

  Was there an inflection point in the evolution of the science and the way in which we were studying the microbiome, in which things flipped from this paradigm of all these microorganisms are pathogens to perhaps there's something more complex happening here?

• 7:50Speaker 01

  Yeah, hard for me to pinpoint any one era or set of events. I think just like what happens usually in science and biomedical research, it's a gradual process to get people to accept new paradigms, new hypotheses. But I'd say somewhere in the last 15 years or so, this notion that bacteria could actually be good for us, or that their bacteria are not harmful, exclusively harmful, became acceptable in biomedical research. And I'd say about 10 years ago, became a little bit more, and maybe you know as well from your perspective, became more mainstream in the lay public and let's say the non-science communities.

• 8:35Speaker 01

  We started seeing, I remember old commercials with Jamie Lee Curtis selling probiotics about a decade ago.

• 8:40Rich Roll?

  Yeah, yeah.

• 8:40Speaker 01

  I thought to myself, maybe that's when like the microbiome has arrived, right? Is that, you know... Actually seeing, you know, commercials on television for particular organ. I think it was like Align. I forget what the actual product was. But certainly nowadays, you know, as we sit here in 2024, I think there's just, not just a lot of acceptance, but a lot of enthusiasm and, you know, hope that the microbiome is going to lead to ways that we can improve human health. And I firmly believe that's the case. I feel like we have a long way to go. Again, happy to discuss that. But I think we're on our way.

• 9:13Rich Roll?

  Caltech has been your home since 2005?

• 9:16Speaker 01

  2006.

• 9:17Rich Roll?

  2006. You teach a couple of classes a year, but predominantly your time is spent in your lab. Can you talk a little bit about why Caltech is such a hospitable host? To, you know, pardon the pun, for the work that you're exploring?

• 9:36Speaker 01

  You know, at Caltech, there's sort of this culture of reaching for the stars and doing things that no one else dares to do.

• 9:42Rich Roll?

  Sort of a Manhattan Project ethos, right?

• 9:46Speaker 01

  It really is, right? You know, I think in some ways like the crazier, the better at Caltech, right? You know, within reason, obviously, but that's, you know, again, someone's got to take chances, right? If you're just doing, you know, incremental safe science, you're going to get what you, what you set out to do, and that's small progress, right? But if you want to make these quantum leaps in both discoveries and changing, you know, the paradigms and changing the way people think, you got to take some chances along the way, and you're going to succeed and you're going to fail. And this is, again, built into the fabric of Caltech. It's one of the things that I feel, not just make it unique, but just a really fun place to work.

• 10:23Rich Roll?

  Hmm. A large portion of your focus in your work is around this thing called the gut-brain axis, which is really a way of saying the way in which the gut communicates with the brain and the brain communicates with the gut.

• 10:39Speaker 01

  Yeah.

• 10:40Rich Roll?

  Can you elaborate on?

• 10:43Speaker 01

  A further sort of more descriptive, you know, elaborate on that definition? Yeah, you're accurate. That is, that is, you know, you know, in, in general, what the gut-brain connection is, two organs, two organ systems talking to each other, right, and communicating in, in real time.

• 11:02Speaker 01

  I'll talk about sort of the mechanisms in a minute, but again, I think this is not too far-fetched for most people to believe, right? If you're in a stressful situation, you know, the most likely outcome isn't that your brain hurts, but that you might get butterflies in your stomach quite quickly, right, within seconds even, right? And for those of us paying attention to the gut-brain connection, oftentimes when I have a disturbed, you know, gastrointestinal tract, maybe I ate something, or maybe I have a GI infection, you know, I'm not thinking as clearly as I normally would, right? And I think that's primary, meaning that there is, you know, this altered communication that, that affects the way, the way our brains work.

• 11:44Speaker 01

  And some of this, actually, the COVID research is, is diving into some of this as well. There's, there's some leading theories that, that long COVID, you know, may be, you know, manifest through the, the effects on the microbiome, right? Interesting. And so I think that's going to tell us a lot about these circuits. But to answer your question, there are a number of different ways, like conduits, that, that, that connect the gut and the brain. And of course, this is true for almost all, all organs are talking to each other in real time, but specifically in terms of gut and the brain, there are neurons, nerves, that innervate the brain, meaning that connect the brain into the gut. The organ system in our body that has the second most number of neurons is our intestine. Some people call it like the little brain, right?

• 12:28Speaker 01

  And then there are nerves that actually connect it to, and so, you know, just essentially like a fiber optic, you know, network that, you know, in, you know, very rapidly can transmit signals, you know, between the two organs. There certainly are, you know, other pathways, like small molecules, bacterial molecules, or molecules from our diets that get into our bloodstream and make their way into the brains in really interesting ways. Right, you know, so one of the, the, uh, you know, hurdles to getting, you know, a lot of drugs to work, like, think of like, sleep medicines, or even anxiety medicines, or many other drugs that have to get into the brain, is that it's hard to cross the blood-brain barrier. It's hard to get things into the brain. Bacteria figured this out.

• 13:09Speaker 01

  And so there are dozens and dozens, potentially hundreds of molecules in our brain that come from our gut bacteria, nowhere else. So they figured out how to get these molecules into, into our brain, and vice versa. You know, a lot of hormones, neurotransmitters, made in the brain can affect the gut, and so it's bidirectional. And then the other major pathway is the immune system. So this is really more recent, in terms of research, but, um, a lot of evidence suggesting that, you know, a lot, our immune cells, the majority of which are in our intestines. So as you and I are sitting here today, seventy percent of our immune cells are in our gut, not in our blood, not in other tissues, but they're in our intestine. What we and others have shown over the years is that these immune cells are essentially being educated,

• 13:52Speaker 01

  primed, they're changing their phenotype, they're changing their function while they're in the gut. And very recent research shows that those same immune cells can now traffic to the brain, or very, very close to the brain, such that they carry those signals that they, that they received initially in the intestines, and then transmit that signal into the brain. So I think there's gonna be a lot more that we learn about how the immune system connects these two tissues. Uh, but I think, again, it's pretty intuitive that there is, you know, real-time communication between the gut and the brain, and this is what we leverage, right? We leverage, uh, you know, trying to understand what are the organisms in the intestine, what are they doing, and how do they use these pathways to send their signals to the brain? Sometimes for effects that are harmful, or what we deem to be harmful, right?

• 14:36Speaker 01

  Uh, I'm happy to talk about anxiety, I think anxiety can be a bad thing, it can be a good thing, right?

• 14:42Speaker 01

  But in other cases, and I think there's, you know, very little argument that something like neurodegeneration is very bad, it's a, it's a harmful effect. And at least in animals, and the human work is being done as we speak, but at least in animals, I think there's a lot of convincing evidence that neurons die in the brain, in, let's say, Parkinson's disease models, or Alzheimer's disease models, and that these effects, this neurodegenerative effect, is, you know, modulated, maybe not caused, but modulated by our gut bacteria.

• 15:11Rich Roll?

  You mentioned the millennia or the, you know, eons of time in which, you know, humans in this symbiotic relationship with, with microbiota evolved to kind of mature these pathways and this superhighway of communication between the gut and the brain and how we, how our immune system operates. Is there, I'm curious, is there evidence to suggest that the microbes have evolved in tandem with how humans have evolved? Like, is there some indication that, that there's, there's adaptations in the microbiota to make them more optimized to be in service to the human machine?

• 15:56Speaker 01

  No direct evidence. It's hard to make evolutionary discoveries.

• 16:01Rich Roll?

  Yeah, that's a, it's more of a, kind of more of a philosophical question, I guess. I don't know how you would prove that out.

• 16:06Speaker 01

  Yeah, it's, it is hard to prove. Even evolutionary biologists working in many other systems often set up models that are predictive of what happened millions of years ago. But of course, you can, you can never fully and rigorously prove it, right? And I think that's the same for, for, for the microbiome. Maybe one piece of evidence that comes to mind that speaks to this co-evolution, the sort of like lock and key, you know, relationship that we have with our, with our gut microbes is the vast majority of the organisms that live in the human intestine live nowhere else in ecology. They don't live, they live in other mammals. Some of them will live in other mammals, not humans. But we have human-specific organisms as well. But they don't live in aquatic or terrestrial

• 16:47Speaker 01

  ecosystems. They're not the same bacteria that live in soil or seawater or live on plants, right? And so really this, this nice, you know, sort of both symbiosis, but speaks to co-evolution between, between those organisms. And something we chatted about a little bit earlier is, you know, the effect size of probiotics versus organisms that evolved in humans. So again, the vast majority of commercial probiotics come from dairy products. And, you know, they have some activity, but research is telling us that the organisms that evolved with us for millennia. Are probably more potent in activating our immune system or modulating our metabolism or our nervous system. And I think, you know, a lot of that is still experimental.

• 17:31Speaker 01

  You know, it's very few commercial products that, you know, come from the, from the human microbiome. I think we'll see more in the next few years, but if you put them side by side and compare their effects, you know, clearly the organisms that evolved in humans seem to have stronger effects. And there's just a lot of molecular work again, not, it'll be very difficult to prove, you know, there was actual co-adaptation, co-evolution. But a lot of microbial molecules that bind our receptors, you know, these are like, you know, proteins or how our cells, you know, you know, know what's in their immediate environment. And a lot of those pathways essentially look like they've been hijacked by, by gut bacteria, meaning that, let's say, you know, you pick a cell, let's say an immune cell has a receptor

• 18:16Speaker 01

  on its surface, so it knows, you know, is there a bacteria or is there some damage in the area that it needs to then repair? So it has receptors to then sense its environment. Bacteria figure out ways of actually sending their own molecules to, to bind those same receptors, to activate those same receptors, and then essentially co-opt them to do things generally that are good for us, but are also good for our microbiomes. Right. Meaning like they- It's a win-win. It's a win-win, right? And that's exactly, that's exactly, I think, the framework that makes sense, you know, I mean, the microbiome can go awry, can, you know, be the source of what we may, may consider an illness. But by and large, microbes want to set up an environment where they can thrive, right?

• 18:59Speaker 01

  And going back to what we discussed about, about, you know, having a healthy immune system, the healthier we are, the better we are at fighting infection, the longer we live, the more of a, you know, hospitable, you know, environment they have- Right. Right, for themselves, right? And I think the gut, you know- Is is nirvana for for bacteria because it's, you know, heat controlled, moist, plenty of nutrients.

• 19:24Rich Roll?

  Mm hmm. Constantly being fed.

• 19:26Speaker 01

  Constantly being fed and and having ways to be shed, right? And you're, you know, we're moving around, we're spreading these organisms, which is what, you know, really that they want to do. They want to spread in a non-infectious way. And so I can't think of many other environments where bacteria can thrive as well as they can in in our intestines.

• 19:43Rich Roll?

  So when we're functioning optimally, the neural networks that communicate between the gut and the brain are functioning properly. The circulatory system that's also involved in this communication network is also functioning properly. Everything is in balance. But disease occurs, as you're discovering, when these systems get disrupted or dysregulated. So talk a little bit about some of the causes or indicia of that dysregulation.

• 20:19Speaker 01

  It can take many forms. For example, immune imbalance, right? So if our microbiomes are programming, that might be a strong word, but I think it conveys the message, are programming our immune system. If that communication or if that, you know, relationship breaks down, then there's a consequence, right? So one example that I think is fairly mainstream would be, you know, the hygiene hypothesis, for example, is where the hygiene hypothesis proposed is that due to increased sanitation, due to cleaner lifestyles and antibiotic use and preservatives in food, we're just less associated with the microbial world than we were, you know, generations ago.

• 21:02Speaker 01

  And the consequence of that is that as we've essentially disassociated ourselves from microbes, the rates of allergic and autoimmune diseases have increased, and they've increased in Western populations where sanitation and antibiotic use are more prevalent, right? And so the hypothesis then, you know, essentially postulates that there are bacteria that we were associated with and viruses potentially. That we were associated with generations ago, which were priming our immune system. And you know, balancing our immune system in ways that prevented us from getting allergies or autoimmunity, right? And as we've again, you know, broken that relationship, as we've disassociate ourselves from microbes, our immune system on its own doesn't function the way it did when we were

• 21:47Speaker 01

  colonized with this multitude of different organisms, right? And that's led to, again, it's not, I mean, you can't argue the fact that rates of allergy and autoimmunity have increased. And this is one hypothesis. This is one mechanism by which microbiome may be involved, but there's certainly plenty more.

• 22:05Rich Roll?

  Extrapolating on the hygiene hypothesis, it would follow then that overuse of antibiotics, perhaps even more acutely when somebody's young, or cesarean births, anything that is depriving an individual and perhaps more specifically, a young individual from exposure to a diversity of the necessary microbiota required to make these systems function, you know, right optimally is going to be an impairment.

• 22:34Speaker 01

  That's right. And I would also add, you know, the diet, the preservatives in food, the type of food that we're eating that's just not nourishing our microbes the way it used to, the lack of human contact. I mean, just think about how we live, you know? I feel like we live in boxes, right? We go from one box to another. It's not the way we evolved. And we acquire, you know, our initial set of organisms from our mother during birth in the birthing canal, in the birth canal. But we are then colonized and we build this consortia of organisms over the first several years of life. And that comes a lot through human contact, right? And you can just imagine how people lived, you know, two, three generations ago, you know, and further back versus how we live now.

• 23:17Speaker 01

  And so I think that, you know, we've also broken, you know, those mechanisms by which we'd be exposed to additional organisms. And what that's led to, and there's, you know, pretty good evidence for this, is the fact that, you know, in the Western world, we're just less colonized. We just don't have the diversity of organisms that people in the developing world do. And that suggests that, you know, that millions or even, you know, hundreds of years ago, that our microbiomes look very, very different than they look now.

• 23:47Rich Roll?

  Is there a time sensitivity around human development where this is a much more pressing issue? Like I mentioned, young people, because my sense, and correct me if I'm wrong, is that when you're young, this is when you're kind of building those systems, much like a young person can learn a language more quickly than an older person. Like, once you get older, is it hard to kind of course correct or rectify, you know, a situation that was less than optimal from, say, antibiotics, or being overly hygienic, or what have you during like the, you know, the infant phase of a person's life?

• 24:27Speaker 01

  Yeah, you know, there's been a lot of evidence, a lot of studies that have looked at both the prenatal period and the first few years of life, right? Because again, that's when we're assembling our microbiome. So what I would also add is, in utero, the priming that we're getting during our initial development from our mothers, right? So even though the best evidence that we have now is that the fetus is sterile, meaning that's not colonized by microbes, it's still being, you know, exposed to many, many molecules, hundreds of molecules that are being made by the microbiome of the mother, right? So the mother's microbiome is important in that development. And that's just, not just brain development, but immune system development, metabolic development, you know, not really like organ development, you know?

• 25:09Speaker 01

  I don't think that that's going to lead to, let's say, you know, sort of developmental issues, right? You know, they're obvious, but just something where the, you know, the actual development of particular organ systems goes awry a little bit. So it's not that you'd see the difference, but, you know, over time, it may manifest differences. And again, a lot of evidence because it's been looked at. And in the first few years of life, you refer to cesarean sections, and there's been research around that, and how, you know, kids born by C-section are more prone to allergic reactions. Those that have gotten more antibiotics in their first few years of life have more depleted microbiomes, are more, you know, prone to allergies, and later on in life, autoimmunity.

• 25:53Speaker 01

  But what we really haven't looked at, and it's really Emerging area is what happens later in life. And so even five years ago, the dogma was that our microbiomes are pretty stable after age three or four. Right. And more recent research, set of papers that have come out just in the last year or so, show that there's a lot of heterogeneity and a lot of diversity in our microbiomes that's tunable in our adult, you know, years, right? It's just the way we had done the previous studies just didn't capture this data.

• 26:22Speaker 01

  Oh, that's good news. Right. And so, good or bad, right? And so, meaning that we can correct a trajectory on the microbiome that may be pathogenic, that may be disease associated, but that we can go from a healthy state potentially to an unhealthy state. So just to be clear, I'm not saying there's data for that. I'm saying that there's the possibility of that because our microbiomes are just more malleable, just more flexible than we thought that they were. And the best evidence for that comes from a number of studies that have just followed people just in their natural lives over time, right? You know, when they lived in one geography and moved to another, or when they lived in one habitat and started, you know, living or cohabitating with other people, right? Within days of moving in with somebody, you're now mixing your microbiome with that person, right?

• 27:07Speaker 01

  And so, you know, so now if you extrapolate, again, the rest of this is just conjecture. But if you now extrapolate out and say, all right, if the hypothesis that many of us believe, where the microbiome dysregulation, some change in the composition of the microbiome can predispose to disease, if that is the case, again, you know, I believe it is, and I think we'll show in humans over the next few years that that's the case. One can then imagine that diseases that we don't normally associate with, you know, infection, normally don't associate as being communicable, maybe, may actually have that component to it. So let's say you, you know, cohabitate with someone whose microbiome, you know, is, you know,

• 27:51Speaker 01

  pathogenic, is altered in some way that isn't healthy. That mixing of, you know, for one example could be is that they have an organism or more of an organism that's driving inflammation, for example, right? If now you start being exposed to that organism and you're colonized. Become or increased in number of that organism, then you may not develop an inflammatory reaction, right? But I want to be cautious about what I'm saying is, you know, I don't want to ostracize particular disease populations, nothing of the sort. These are, you know, probably going to be, you know, when it's all send on low likely, low likelihood events, meaning that, let's say, I move in with somebody who has a microbiome driven disease, right? And I mix my microbiome, it doesn't mean I'm going to get that, it doesn't mean I'm going

• 28:36Speaker 01

  to get sick. Other factors are involved, such as genetics, and I think genetics are really, really important, meaning that a person could have a dysregulated microbiome, but if they have a healthy genetic landscape, they're probably not going to develop disease. And I think we should talk about this, this gene environment interaction, because I think it's crucial to how the microbiome works. But, you know, going back to analogy, if I move in with somebody and I am genetically vulnerable, but my microbiome was healthy, my microbiome was robust, I didn't, I didn't show signs of disease, but now that I'm, you know, exposed to a harmful organism, that combined with my susceptibility, my vulnerability on the genetic level, together may, may predispose me and I may now start developing symptoms.

• 29:20Rich Roll?

  Right, right, right, right. Yeah, that's super interesting, and I appreciate the qualifier, because that, you know, without that, you can just imagine the clickbait headlines that would come from that.

• 29:30Speaker 01

  I've been very cautious about this, in fact, I resisted.

• 29:34Rich Roll?

  There's a lot of hype and a lot of kind of people out over their skis on, you know, in this field, in terms of like how the science is getting translated into mainstream awareness.

• 29:43Speaker 01

  Correct. And, and I had contributed to that for, for many years. I've tried to become much more conservative in, in the way I extrapolate from the data itself, right? And to this point, I, it was about a decade ago, I thought about writing an article about, again, you know, the microbiome being a mediator of non-communicable diseases, a disease that we never considered to be transmissible. And I never wrote that article.

• 30:11Speaker 01

  Other people now have written articles of that sort. And it's fine, it's fine to put those hypotheses out there. But again, I do worry, right? I do worry that we may be overextending the knowledge base, actually worrying about things that may not happen. But now, at least, maybe the bright side is, once the hypothesis is proposed, then people will test that hypothesis, so we will know. But again, these are going to be low likelihood events, even if it's true, and I have no reason to believe it's true. For example, is Parkinson's contagious? There's no real evidence to suggest that that's true. There's some epidemiologic evidence, meaning that a spouse of a person with Parkinson's is more predisposed.

• 30:55Speaker 01

  In fact, neurologists are more predisposed to Parkinson's than the general population. But there are a number of other potential explanations for that that go well beyond the microbiome.

• 31:13Rich Roll?

  What do we know or not know when it comes to the genetic markers that would create that type of vulnerability?

• 31:20Speaker 01

  There's probably a lot of evidence, there's probably a lot of evidence from the genetic world, meaning all the genetic studies, that have not yet been linked to how the microbiome affects the outcomes of those genetic predispositions. These are really two camps, research areas, that are by and large separate from each other. And there may be some conflict between the approaches that geneticists use and people who study the environment, for example. Microbiome, you know, a major component of the environment. And that tension is that genetics, you can explain genetics pretty easily these days,

• 32:02Speaker 01

  a genetic predisposition to disease, because DNA sequencing has become so advanced and the algorithms that analyze the sequence data have advanced so much that we can pretty much get a good genetic fingerprint of an individual. And then people do these large genetic studies, like, in some cases, thousands, tens of thousands of individuals with a particular disorder, and then you can then link even low probability genetic predispositions to that disease.

• 32:28Rich Roll?

  Right.

• 32:30Speaker 01

  All that research, a huge, vast amount of work, really hasn't been tied to how the environment then modifies those genetic predispositions. I personally believe that the majority of our genetic predispositions are modified by our environment. Right? If you were to, let's say, list the top 100 diseases that affect humanity, I'm going to say 90% or more are a product of gene-environment interactions, not solely driven by genetics, not solely driven by the environment or the microbiome.

• 33:00Rich Roll?

  And by environment, that would include lifestyle decisions?

• 33:03Speaker 01

  That would include many, many things, right? So lifestyle decisions, let's say, you know, diet, right, and exposure, like alcohol, drugs, or other exposures, but, you know, pollutants in the air, things that we can't control, right? I mean, maybe we're sitting in an area where there's arsenic gas that's seeping up from the ground. That happens sometimes, we don't even know, right? Heavy metals in our foods, preservatives, many other environmental risks. And I really think these both compound over time, and so, you know, maybe, you know, contribute to age-related disorders. In other words, we have a historical record in our body of all these harmful molecules that we've been exposed to. We've had the same genetics in our lives. Over, after some time, we just pass a tipping point where those environmental triggers

• 33:47Speaker 01

  just, you know, become so strong that, coupled with the genetics that, you know, manifest the disease, right? And so, you know, but again, you know, I study the microbiome, so, you know, the microbiome, I think, is a major part of our environmental exposure, right? Just go back to the fact that, you know, hundreds, maybe thousands of molecules in our bodies are, come from our microbiome, come from our microbiota. And so they're constantly sending these chemical signals into our bodies, and our microbiome is changing based on lifestyle decisions, based on other things in our environment as well. So maybe the microbiome can be viewed as a rheostat, if you will, for environmental exposures.

• 34:22Rich Roll?

  And technically, it exists, it exists outside of us.

• 34:26Speaker 01

  Correct.

• 34:26Rich Roll?

  Yeah, it's technically not in our body, it's outside of our body.

• 34:30Speaker 01

  Yeah, and it's changeable, right? Changeable in a way that our DNA isn't, right? I mean, of course, our DNA can be modified in our lifetimes, both in terms of mutations and this other, you know, area of biology called epigenetics, where you're not actually changing the DNA itself, but changing properties of the DNA, and that, you know, is linked to environment. But again, these two camps, if you will, really haven't merged in terms of, you know, taking what we've learned from all these genetic studies, and then now asking how do those genetic risks, how are they modified by the microbiome, right? And, you know, my hypothesis, something I've written about a little bit recently, is that, you know, many of us have genetic predispositions, but maybe we don't have disease because

• 35:13Speaker 01

  our microbiomes are robust, they're sort of filling in the gaps, if you will, right? That the genetic vulnerability exposes us to. But if my microbiome then becomes, let's say, again, I've lived my whole life with a genetic predisposition, my microbiome was healthy, I didn't show symptoms, but something corrupted my microbiome, I lost that resiliency, I lost that, you know, the compensation that my microbiome was providing, maybe now, or it can even go in the other direction, where microbiome becomes pathogenic, it's now sending these harmful signals that combine with the genetic vulnerability to result in disease, right? I think, again, this is going to be the majority, and I want to make this point, is I think this is going to be the majority of the way that our microbiomes interact with us in the context of disease, right? So I think there's only a handful of

• 35:56Speaker 01

  cases where the microbiome actually will cause the disease. I think in most cases, it's networking, or let's say modifying genetic or other predispositions. And so that's where I think the microbiome sort of fits in our biology.

• 36:10Rich Roll?

  Right. Speaking of a pathogenic microbiome, walk me through what led to this discovery that there is a connection Between Parkinson's and the gut microbiome.

• 36:28Speaker 01

  Yeah, this was a hunch that we had many, many years ago. Again, we study mice, animal models, so much, much easier to test than in humans.

• 36:40Speaker 01

  But the actual evidence, like most things that we study, the actual evidence goes back decades. In fact, sometimes centuries. And so the, what, you know, I won't go in chronological order in terms of what I learned to make us think that maybe there was a connection.

• 36:55Rich Roll?

  But we do have to credit Parkinson himself for what he said in 1870, right?

• 37:01Speaker 01

  That's exactly where I was going, right? It's exactly where I was going. So in 1817, James Parkinson wrote the Essay on Shaking Palsy, where he talked about case studies of individuals that had tremors and gait and posture instability, which is Parkinson's. It was later named after, he didn't name it Parkinson's. It was named after him, you know, I think a couple of decades later. But then he also talked about the GI symptoms, essentially constipation. And then in one of those case studies, he gave a patient a bowel cleanse, essentially a laxative, and said that their motor symptoms or their behavioral symptoms improved. And so this is, you know, the point I'm trying to make is none of this is new, right, to neurologists. It just hadn't been studied.

• 37:42Speaker 01

  In fact, I've asked many of my neurologist colleagues, like, why weren't, you know, why was this gut-brain connection not made previously? In Parkinson's, when you see patients who are complaining about constipation all day long, right? And the answer I get more times than not is that, I'm a neurologist. What can I do about their GI issues, right? Which sort of speaks to our medical system and how, you know, there's a lack of integration across disciplines.

• 38:07Rich Roll?

  Right, everybody's siloed in their own respective discipline.

• 38:10Speaker 01

  It happens, it's the same in science as well, right? And so, you know, obviously, I learned a little bit about that literature, but read mostly about the fact that, you know, somewhere between 50 and 80% of Parkinson's patients will have clinical-grade constipation years before their first motor symptoms, years before they're ever diagnosed with Parkinson's. Right? And just to be clear and fair, it's not just GI symptoms. They'll have olfactory deficits, so loss of smell, REM behavioral sleep disorders, sleep disturbances called REM behavioral sleep disorder, and maybe even psychiatric issues like depression. So there's this host of comorbidities in what is called the prodromal phase

• 38:54Speaker 01

  before the actual diagnosis. The constipation is quite prevalent. And again, you know, it was a clean slate of research at the time. There was no evidence for or against this hypothesis, just this correlation between GI symptoms and motor symptoms. And so we took a chance, and I credit Tim Sampson, who was a postdoc at The Times now, a professor at Emory, for just being intrepid enough to just ask that question of is the microbiome involved in Parkinson's? And we did a very, very simple experiment. We took mice that were genetically predisposed to developing symptoms of Parkinson's, and we just cleared out their microbiome. Right? It's a very artificial system, right? So there's no sterile microbiology, sterile people or animals, right?

• 39:39Speaker 01

  But we just artificially made them sterile, and all their symptoms went away. Their gut symptoms went away, their motor symptoms went away, their brain inflammation went away. And that classic hallmark of Parkinson's, which is, just to get into weeds just a little bit. So it's widely believed that Parkinson's is caused by aggregation of a neuronal protein called alpha-synuclein, so a protein we all have. You know, many, many organisms have this protein in their neurons. And when this organism, or when this protein, this molecule clumps, it essentially prevents cells from performing their normal functions. And eventually, those cells will die because they can't deal with the stress of this, like, you know, hairball of protein just building up inside.

• 40:19Rich Roll?

  And this is happening in the neurons in the brain?

• 40:21Speaker 01

  It's happening in neurons in the brain, but it's happening in neurons all over the body, including the intestines, right? And we were the first, one of the first groups to show that in fact it was happening in the intestines of these animals as well. And it's not that we did anything revolutionary, we just looked somewhere that people hadn't looked before, right? And so again, that simple experiment, just removing the microbiome, removed this pathology's alpha snuclean aggregates, in addition to all the symptoms. And, you know, at that point, I actually remember sitting in my office and Tim walking in with the data. I felt like something was hap-- I mean, it was clear that something was happening. And of course, that experiment doesn't tell us exactly what, it's sort of a go-no-go experiment, but this was 2013 or so.

• 41:02Rich Roll?

  Wow.

• 41:03Speaker 01

  And since then, we've made a number of discoveries that, again, keep reinforcing this hypothesis.

• 41:08Rich Roll?

  How was that data received at the time?

• 41:12Speaker 01

  In the Parkinson's world, it's been received quite well, meaning that even, you know, neurologists, you know, neuroscientists, people, you know, historically working in the field, have been very, very open-minded to this hypothesis. Even geneticists, who tend to be, you know, quite skeptical of the microbiome, for reasons that I just discussed a few minutes ago, seem to embrace this, this concept. Again, it's not, it's not a fact yet, right? Still, you know, you know, well, I'll tell you this, I believe that it's true in mice, right? I believe that this, you know, connection between microbiome, genetics and Parkinson's, it's true in many animal systems, we just haven't shown that to be true in humans yet, right? And again, all that work is currently underway.

• 41:56Speaker 01

  And so, the reason why I believe it's been well-accepted in, you know, a very traditional research space, neurobiology, neuroscience, is because everyone in that field knew about these GI symptoms, knew about the gut issues, right? I'll give you a contrasting area, where there's, where there's a lot of skepticism, a lot of pushback, and that's in autism. So, the other portion of our laboratories worked on the connection between the microbiome and behavioral disorders, neurodevelopmental disorders, primarily autism. And there, we don't have, like, the smoking gun, we don't have these connections that are so obvious in Parkinson's, in the autism world, or at least in terms of like--

• 42:37Speaker 01

  You know, the symptomology in an individual with autism. And so we others have shown in mice, many other groups have shown in people, that there's this connection between the microbiome and autism. It's been, again, very, very tough treading in that space. And, you know, I have to say, I'm not, you know, I can see where the skepticism is coming from, right? Because we have, I don't feel as a field, we've done the experiments to even convince myself that the microbiome is fundamental to autism, right? And the microbiome affects so many other systems, but is it really contributing to this disorder or not? That's still an open question, right?

• 43:20Speaker 01

  And I feel skepticism is healthy, it keeps us on our toes.

• 43:23Rich Roll?

  Yeah, I appreciate that. But the studies that you have done with autism and this 4EPS molecule are pretty compelling and fascinating. Like, walk through the kind of, you know, the mechanics of how this molecule finds its way into the wrong place. And perhaps, you know, according to your hypothesis, has some correlative or causative effect.

• 43:48Speaker 01

  Yeah, we showed in a 2013 paper that fourth phenyl sulfate, 4EPS, that you're referring to is elevated in a mouse model of autism and is modulated by the microbiome, meaning that it, based on the microbiome of the animal, it was either increased or decreased. So that's just a correlation. More recently, we published that, in fact, that molecule in and of itself is able to drive behavioral disorders in animal models, meaning that we set up experimental systems where we can artificially elevate the levels of this molecule, which comes exclusively from gut bacteria. We don't make it, it's not in our diet. Flies, worms, more primitive organisms don't make this molecule. To the best of our knowledge, only certain types of bacteria make this molecule. Why?

• 44:33Speaker 01

  The molecule is made, I still don't know, right? So maybe there's an evolutionary accident. Maybe there's some, you know, adaptation that's relevant to the function of the organism. That's still an open question. But based on that, we showed, based on saying of these experimental systems where we can elevate levels of 40PS, we showed that the animals develop many symptoms of autism, but primarily develop anxiety, anxiety-like behavior. And so in addition to that preclinical or animal work, we showed in humans that this molecule is elevated and that particular drugs can lower the levels of this molecule. And so still a lot of correlative studies in humans, but suggesting that what we're

• 45:16Speaker 01

  identifying mice, we can actually replicate in terms of the elevation in humans, meaning that a person with an autism diagnosis is much more likely to have elevated 40PS in a person than a neurotypical individual. Right. Without the diagnosis. Whether or not, so I do believe, based on experimental systems, that this molecule is driving behavioral changes, primarily anxiety, but social changes and vocal, you know, language changes as well in mice. In humans, the jury's still out on whether or not we've just observed a correlation, an association between the two things, or whether or not that molecule is actually driving, you know, any feature of autism. That's still all work in progress.

• 45:58Rich Roll?

  The way my layperson brain understands this is that 40PS is a derivative of tyrosine, tyrosine being an amino acid that we get from our food. So we eat food, we eat protein. This particular bacteria takes the tyrosine, creates the 40PS. It leaves the gut, it enters the circulatory system, it travels up to the brain, and it passes the blood-brain barrier. For some reason, the brain lets it in, and that's where it's doing its damage. At least in mice, is this correct? Is this how I understand this? I'm trying to, I realize I'm being incredibly reductive.

• 46:40Rich Roll?

  I'm trying to, you know, create a visual image of like how the the mechanics of this work. Because we're dealing with the the epithelial, you know, the gut lining and its permeability. And we're also dealing with the blood-brain barrier. And these are, you know, critical, you know, sort of walls where decisions are made about what goes in, what's what stays in, what gets to go out, what's allowed into the brain, et cetera. And and part of the dysregulation is around like the wrong things, you know, leaking out and being let into the brain.

• 47:14Speaker 01

  I firmly believe that's true. And you you're right in terms of the way you drew the sort of the trajectory of where the molecule is made and how it travels through the bloodstream and into the brain. That's all accurate. So as I referred to several minutes ago, is that the fact that microbes have figured out how to get their molecules into the farthest reaches of our bodies, right? So again, those transporters, those mechanisms to cross the gut epithelium, the mechanisms to cross the blood-brain barrier exist because our body uses, you know, those pathways to, you know, for signaling, you know, I believe bacteria have learned to hijack some, you know, those very, you know, those same highways to send their signals. And so, you know, as you said, we can trace the molecule from the gut through the circulation. It's actually modified in the liver, goes through circulation through the blood-brain

• 47:59Speaker 01

  barrier into the brain. And we'll go one step further is that we've shown that particular brain cells are responding to four ethophenylsulfate. They're not neurons. Neurons may also be be responding to this molecule. We don't, we haven't excluded that. But we know that there are cells called oligodendrocytes. And their biology, their actual maturation is regulated by this microbial molecule. So what oligodendrocytes do, just in a nutshell, is they myelinate our neurons, our neuronal axons. So what that means for for, you know, let's say, the non non neuroscientist is think of the the electric wire in your house. It's coated with with, you know, a rubber coating, right, to allow long electrical impulse to travel and not dissipate. Our neurons do the same thing.

• 48:41Speaker 01

  They send projections, sometimes, you know, many, many inches, if not, you know, varies, you know, long, you know, like two or three feet. And so so that that signal doesn't, you know, isn't reduced, doesn't dissipate over time, we have this myelin sheet that coats the long axons. That's what oligodendrocytes do. So they actually, you know, create this myelin, you know, and this, you know, Ability for neurons to send their signals over long distances. And so when oligodendrocytes don't develop properly, they, there's a reduction in the ability to myelinate neurons, and that just changes brain function. It's called connectivity, meaning how different regions of the brain are talking to each other. A lot of this is regulated by oligodendrocytes, right, because of their ability to myelinate neurons.

• 49:25Speaker 01

  And this micro molecule regulates oligodendrocyte biology. So we think we have a handle on how, at least this one molecule is working. There's many others that we haven't studied. And everything I showed, everything I just described was done in mice, but it tracks very, very well with human studies, because this changes a myelination pattern, changes in connectivity, how regions are talking to each other in the brain. All that's been shown in people, right? So in observational and brain scan studies, we know that that's true in autism and a lot of other neurodevelopmental conditions. So we think we're on the right track in terms of understanding how the molecule is working.

• 49:59Rich Roll?

  And with respect to Parkinson's, is there some kind of analogous mechanism that's similar to what you laid out with autism?

• 50:07Speaker 01

  Yeah, there's, and I want to also preface this by saying that what I described some minutes ago on autism is probably one of multiple, you know, mechanisms.

• 50:17Rich Roll?

  It's working in concert with many other things, yeah.

• 50:19Speaker 01

  Yeah, and there are probably other things that are happening in parallel that have nothing to do with 4EPS, right? And so, so there's probably multiple ways to get, get to the same outcome. And so likely true in Parkinson's as well. So one of the mechanisms that we've shown in Parkinson's is, so going back to aggregation of this neural protein, alpha synuclein. This is, I think, maybe a more famous example is, is A beta, amyloid beta in Alzheimer's. So again, these clumps that form in, in the Alzheimer's brain, it's something very similar is happening in Parkinson's, right? So again, highly and widely believed to be the causative pathology of Parkinson's is aggregation of alpha synuclein. So what we showed is that there are bacterial proteins

• 51:02Speaker 01

  which can induce alpha synuclein aggregation in the intestines, right? So bacteria that are elevated in human Parkinson's, we can take those organisms. Put them into mice and those organisms can now induce aggregation of alpha snuclean when previously there was no aggregation.

• 51:19Rich Roll?

  And produce produce similar symptomology in those mice.

• 51:23Speaker 01

  And and and the origin is the gut, right? Because we're not adding the bacteria or the bacterial protein to the brain. The bacteria reside only in the intestine. And in this case, unlike 40PS, the bacterial molecule that's essentially triggering this pathway that's setting things in motion stays in the gut, right? It just starts a cascade of events in neurons of the intestine where alpha stokin aggregates. And once alpha stokin aggregates, it sort of self-propagates itself. So there's this, it's called the amyloid hypothesis or the pre, sorry, the more accurate, the prion hypothesis, where a protein misfolds, it forms these clumps, and then it causes more of that same protein to form clumps. So it just sort of spreads, right?

• 52:04Speaker 01

  And so, once the, you know, so like, you know, horses out of the barn, if you will, in the intestines, this protein aggregation can make its way through the intestinal neurons, up the vagus nerve, which connects the gut to the brain, and into the brain, and then spreads throughout the brain. So it's not the bacterial protein that ultimately causes the disease, it's the bacterial protein triggers this cascade of events, and the neuronal protein then results in in in disease. And so we've shown this a number of different ways in in animals, adding bacteria, adding the protein, you know, doing all those different permutations. Perhaps some of the best evidence for this is that we can, we developed a compound that can drug this pathway, that can inhibit the bacterial protein from from associating with alpha snuclean in the intestine.

• 52:48Speaker 01

  And what's unique about this drug compound, this molecule, this drug molecule, is that it's gut-retentive. It actually never enters a circulation. It's only active in the gut. And this drug works, at least in mice. We don't know in people yet. And so, not only is the cascade started in the gut, but we can inhibit the the process in the gut and then see improvements in behavior, see improvements in brain pathology.

• 53:11Rich Roll?

  So from a therapeutic perspective, the goal is to identify that's that's specific microbe or or bacteria and find a way to target it such that you either kill it or you shut it down or you prevent it from engaging in that process that leads to all the kind of cascade of events that you don't want.

• 53:32Speaker 01

  That's exactly right. And to the best of our knowledge, and going back to the fact that this is almost likely not the only, certainly not the only way that that the gut can be involved in Parkinson's, is that when we now look across human populations, people with Parkinson's and compare them to, you know, household controls, population controls, this organism and this bacterial protein that I just mentioned is found in about 18 to 20% of Parkinson's. And so I think, you know, that suggests that the mechanism we identified is only part of.

• 54:03Rich Roll?

  It can't be singular.

• 54:04Speaker 01

  Yeah, yeah, yeah. Either there's redundancy, meaning that, you know, in, you know, something over 20%, there's a similar pathway that's happening that we just don't know, or there's something entirely different that's happening, right? Or certainly that the gut is not involved in, you know, some potentially even large portion of Parkinson's. And that's all, again, work in progress.

• 54:25Rich Roll?

  Talk a little bit about the relationship to the vagus nerve with Parkinson's, because I know that if you have that nerve cut in surgery, or you have your appendix removed, you become less likely to develop Parkinson's. Like, what does that tell us or not tell us about the mechanisms of this disease?

• 54:43Speaker 01

  Yeah.

• 54:44Rich Roll?

  Like, why not just, anybody who has a predisposition to Parkinson's, shouldn't they just get their vagus nerve cut? Or what is that? There's probably a lot of bad things that happen.

• 54:53Speaker 01

  There's consequences to cutting your vagus nerve. So the vagus nerve, again, it's this bundle of neurons that that go from the brain to many, many different organs. And so when you cut the vagus nerve, there's a lot of side effects to that, like just the strongest of which are like digestive effects, but effects, breathing effects, heart rate effects, a lot of other things as well. And so vagotomy, which is severing the vagus nerve, is likely not the best, best way to solve that problem. But what you're referring to are a number of studies, initially From Europe where they have really good medical records better than we have here. That showed that people who were vagotomized or vagus nerve was cut many, many decades ago. As they age were protected from Parkinson's statistically protected. It doesn't mean that none of them got Parkinson's.

• 55:36Speaker 01

  It means that they were less likely to develop Parkinson's over the years. And the reason why they were vagotomized, I think this is also quite interesting. Is oftentimes the vagotomies were done to control peptic ulcers, so stomach ulcers that would lead to cancer. You know, because people thought this was a consequence of stress. So why do we have ulcers, right? It's because we were stressed. We now know we have ulcers because of Helicobacter pylori, because of bacteria. Right? So it's a sort of funny link back to gut bacteria themselves. But again, so this is not standard these days. So people with, you know, stomach ulcers are not given, are not vagotomized, are given antibiotics. And so again, there was a population of people and as you just rightly referred to epidemiology is suggesting this is the case.

• 56:19Speaker 01

  In mice and rats, there's, I think it's absolutely conclusive that the vagus nerve is involved in mouse models of Parkinson's. And none of this is our work. But people have set up experimental systems where they can trigger, you know, the initiation of Parkinson's like symptoms in the gut. In mice and rats and show that starting in the gut, you know, that pathology, that symptomology can then migrate up to the brain. And the mice develop symptoms of Parkinson's. And then if they cut the vagus nerve in the rodents, they basically see the GI symptoms, but they don't see the brain disorder. They don't see the motor and the movement disorders. And mice and humans, rats and humans are obviously very, very different, but I think there's enough fundamental biology linking us.

• 57:03Speaker 01

  And they only have, their vagus nerve looks just like our vagus nerve, it innervates the same organs as our vagus nerve does. So I think there's, you know, I don't see a reason why mice and rats would be that different in this particular case.

• 57:15Rich Roll?

  Yeah.

• 57:15Speaker 01

  Than than humans.

• 57:16Rich Roll?

  Yeah, I mean, that that leads to my next question, which is. We see so many interesting things in the study of mice and rodents. So few of those things seem to apply to humans when you kind of move up the phylogeny. Like what is the, like?

• 57:35Rich Roll?

  Why is it that it seems so clear in mice and yet this question mark lingers over the human animal? And why can't we perform some kind of studies that would create greater clarity?

• 57:46Speaker 01

  Yeah, I have a pretty advanced thoughts on this one. And so, the vast majority of the basic biology studied in rodents does translate to people. Right? And so, for example, there's dozens of examples, I'll just use the vagus nerve. Right? So again, a lot of vagus nerve biology was first studied in mice and rats, and a lot of that has translated to people, meaning that the vagus nerve works very similarly in the two different species. Right? What hasn't translated, and what I think you're referring to, is drug discovery and drug, you know, the actual efficacy of drugs. Right? The vast majority of FDA-approved drugs were, at some point in their development, you know, tested in rodents. Right?

• 58:30Speaker 01

  And they showed efficacy, meaning that they solved the problem that they were trying to solve. And then, as those drugs were developed, about 90% of them never worked in humans the way they worked in rodents. So, we're pretty good, I think, at understanding basic biology in mice, and then showing that we can replicate the basic biology. What I think we do a very poor job of is taking drugs that are developed in rodents and making them work in people. I'm happy to elaborate on that. I think I have, you know, there are some pretty good examples why I think this is, I think we've essentially set ourselves up to fail, right? In terms of drug discovery, using mouse models that we currently use. Right?

• 59:13Speaker 01

  And so, the vast majority of biomedical research relies on specific strains of mice, inbred, genetically identical clones of mice. Right? And so, you do this because you want to replicate your own data. You want a group of mice to all behave the same so you can actually make a discovery. Right? And so, we are not clones of each other as humans. And so, we've essentially set ourselves up to fail because we're using, we're essentially saying that one person's DNA is going to extrapolate over eight billion people, and that's certainly not the case. Right? But what I think we do even a worse job of is accounting for the environment that these animals live in. Right?

• 59:54Speaker 01

  And so, you and I were exposed to many microbes, infections, stress, other environmental impacts on our bodies. Throughout our lifetime, and there's, as we talked about a few minutes ago, a cumulative impact of our previous exposures, whether they're microbial or toxins or heavy metals, whatever they may be. And so animals in a laboratory live in the same cage, in the same box their whole lives. They have very little to no environmental exposure. We have to filter the air that they breathe. They're eating sterile food most of the time, drinking highly purified water. And so their bodies just don't have that historical fingerprint of all the damage that's been done. They don't drink alcohol.

• 1:00:39Speaker 01

  They don't eat fast food, unless we give them a Western diet. And so you couple that with the fact that we're not modeling genetics properly and we're not modeling their environment properly. We're seeing a narrow sliver of human biology in these animal models. So going back to the basic biology translating is, again, the wiring is the same. The organ systems are the same. So that part translates. But then we expect a reaction from these animals to a drug. And we figure out some condition to make it work in a mouse. Sometimes even contrived, like very, very high doses, for example. And then we go out into a very wild human population, a very diverse human population. And most of the time the drugs don't work.

• 1:01:24Speaker 01

  So I think we should be doing a better part on the front end of diversifying our animal models, of not using these genetically identical, environmentally limited, restricted model systems. I think we should go out and do population studies in people or in animal populations and use that data to develop better drugs.

• 1:01:52Rich Roll?

  I would suspect that it's even more complicated for someone in your field when you're thinking about therapies or interventions that are microbe-based. Because you'd be introducing a microbe into a microbial environment that's not nearly as diverse or complex as the human being. So you'd be less likely to extrapolate anything meaningful from whatever impact that has.

• 1:02:20Speaker 01

  Yeah, that's absolutely true, but I think there are workarounds on that. And so what we're doing, you know, part of our research program now is to develop animal models that are just more reflective of of human lifestyles. So again, diversifying the animal models that we're working with. But then the other aspect that gives me that gives me a lot of hope is that the regulators, the FDA, is quite bullish about microbiome-based therapeutics, right? Again, the purview of the FDA is to ensure safety and tolerability of drugs, right? I mean, it's not their primary concern of whether or not the drug works. They're just the gatekeeper to make sure we're not harming people by putting experimental drugs in them that make the drug is worse than the actual symptom that we're that we're trying to treat, right?

• 1:03:03Speaker 01

  And the FDA's position, I think, has been very clear and consistent for the past decade is that taking a microbe from one human being, putting another person, is a low-risk, you know, proposition, right? So they're very, you know, you know, lenient about giving investigational new drug designation to human-derived, you know, therapies. They have really educated themselves the last decade, so they've called me out three, four times, you know, all before the pandemic. And essentially, you know, you know, these were like, like, learning lessons for them. And I wasn't the only person, many other people out, just to sort of bring scientists in, and so they're they're learning what's on the cutting edge. That's interesting. And what they've done more recently in the past few years is actually develop guidance,

• 1:03:48Speaker 01

  you know, like, written guidance and guidelines for how do you develop probiotics? How do you develop, you know, organisms that come from humans, right? And again, this is not something that they feel is risky, because if, let's say, I were in a chemistry lab and I develop an entirely new molecule, right? And I believe it's going to, you know, bind to a particular receptor or affect a particular cell type that's going to, you know, improve a disease outcome. But that drug has never been in a human being. There's a lot of risk that as soon as you do, something bad's gonna happen, right? It may or may not, we don't know, right? But that's what they try and protect against. They don't see this risk in the human microbiome, because essentially, civilization has done the safety trial over millions of years. Yeah, yeah, yeah. What we should be doing more of, and me and my lab are certainly not the people

• 1:04:32Speaker 01

  who would do this, is taking organisms and instead of, and I'm gonna, I'm gonna actually argue against myself here, instead of testing them in mice for five, 10 years, go directly to people, right? I think the vast majority of the time, the worst thing that's gonna happen is it's just not gonna work. But we'll learn from that, as opposed to doing these intellectual gymnastics in animals and figuring out how they're going to work and then seeing if they're going to actually work. And people, just go directly to people because the worst thing that's going to happen is people are going to get some diarrhea or bloating. But again, that's the majority of the time they're going to have, nothing's going to happen.

• 1:05:07Rich Roll?

  Yeah, yeah, yeah. Low risk, but with this added extraordinary value proposition, that it's a very targeted remedy that goes directly to the one thing that you're trying to address. Like, I've heard you talk about SSRIs, like Prozac, for example, like only 1% of it actually passes through into the brain and does anything. Whereas, if you can really crack this nut and figure this out, it's the difference between carpet bombing your body with something and a very strategic drone attack.

• 1:05:41Speaker 01

  Yeah, I think that's true for all drugs, to be honest with you, right? Is because ultimately, it comes down to effect size. So how potent is the activity of the drug? Whether that drug is a molecule, whether that drug is a living organism, right? Meaning that if it's really potent, and to your point, specific in doing what it's going to do, you're going to see an effect, right? If it's not, if it's, let's say, the effect size is weak, right? Meaning that a person has to be super healthy, a triathlete or something, for it to actually work, then you're going to see a very weak signal in the clinic and probably not going to be able to develop that drug. That's the same with pharmaceuticals, right? I mean, pharmaceuticals, their effect size really matters, right? And that's why

• 1:06:23Speaker 01

  the vast majority, or that's one of the reasons why, the vast majority of drugs that are FDA-approved work in less than 50% of their patient population, right? There are drugs making billions of dollars that work in 1 out of 10 people with that disease, right? But they're still making billions of dollars, right? And so I think, again, there's a lot that you can learn by going directly into the clinic. And again, very low risk in terms of safety. I think we should just be doing more of it.

• 1:06:48Rich Roll?

  It would stand to reason with these discoveries that you've made around Parkinson's and autism, that there would be similar revelations with other neurological disorders. Talk a little bit about what that landscape looks like. Right now.

• 1:07:06Speaker 01

  I would say, in my personal opinion, there's a lot of research going on Alzheimer's. We work on Alzheimer's disease. I think the likelihood that someday we'll have microbiome-based therapeutics or diagnostics or modulators of Alzheimer's is probably very low, right? And I think that's for a couple of reasons. The initial data don't look as strong for, let's say, compared to this Parkinson's. But also, Alzheimer's is a very difficult disease in and of itself, right? I mean, there's a lot of, you know, damage that's done in the Alzheimer's brain prior to our ability to really know if that person is having cognitive issues, right? So I think it's hard to turn that ship around.

• 1:07:50Speaker 01

  I think something like depression is an area where the human data really look compelling, meaning that it's not just that the microbiome is different in a person with major depressive disorder versus a person who doesn't have depression, but the signatures, the way the microbiome changes, appears to make a lot of sense, right? So, one of the strongest pieces of evidence in the microbiome of people with depression is that, this is an interesting topic we can talk about as well, our microbes make neurotransmitters. Like, the vast majority of neurotransmitters that our neurons make, gut bacteria make those as well. What they're really doing, we don't know, right? But a lot of the bacteria that are differential in a person with depression and a person

• 1:08:34Speaker 01

  without depression are these neurotransmitter-producing bacteria. And there's also a lot of evidence showing that there's, study to study, you know, a lot of correlation between the types of organisms that are either up or down in depression versus a person without depression. And so, that signature speaks a lot to me, right? Meaning that, why is it that a person with depression in one geography, in one part of the world, with a different lifestyle, has the same microbial fingerprint as someone on the other side of the world with depression, right? You know, this doesn't happen in autism, this doesn't happen in Crohn's diseases and that happens in allergies. That they're just huge, study to study variation, right? Not so much in depression. And so I think in terms of, you know, this gut-brain area, right? And there's other, you know...

• 1:09:19Speaker 01

  There's other, let's say, inflammatory metabolic disorders that I think the microbiome has a strong likelihood of impacting. Again, we've worked very little, I'd say, on depression because I don't think the animal models of depression are that good. But I think from what I've seen, the human data really suggests that we can potentially modulate depressive activity by using the microbiome. And the other piece of evidence, and this is conjecture, is that there is exceedingly little evidence that there's damage in the depressed brain. So unlike Parkinson's, unlike Alzheimer's, and even a little bit of evidence in autism, much less than your generation, obviously, that there's actually some physical change

• 1:10:04Speaker 01

  to the brain. To the best of our knowledge, there's no physical change in the depressed brain. So it means the wiring is still there. All the components are there. Maybe it's just a chemistry problem. Maybe just the molecules are in imbalance. That, to me, gives me a lot more hope that we can actually modulate those outcomes.

• 1:10:20Rich Roll?

  Is it a chicken and the egg thing, though? I'm imagining, given the bidirectionality of the communication between gut and brain, is it possible that something's happening in the brain that then is signaling the gut to activate those microbes and create those neurotransmitters? Or is there clarity around it beginning in the gut and traveling up to the brain?

• 1:10:43Speaker 01

  Yeah, I think it's going to be case by case, and I don't think we have a good handle on in what scenarios, under what circumstances, it's, let's say, gut first versus brain first. And I'll throw another wrinkle in there. Going back to genetics, is our genetics shape our microbiome. So it doesn't have to be brain reshaping what's happening in the gut, but a person's biology, their DNA, and the way their gut functions, the way their immune system or their metabolic systems function reshape the microbiome. So there is a lot of, our bodies influencing our microbiomes to potentially be different than another person. But then the question, still completely wide open, is what do those changes actually mean? So I'd say we're quite good at measuring the changes.

• 1:11:27Speaker 01

  We're not that great at understanding how those changes affect biology. And that's where model systems like animals come in. Because we can test hypotheses in mice that in most cases are either not feasible or not ethical to immediately test in people.

• 1:11:42Rich Roll?

  But conceivably...

• 1:11:44Rich Roll?

  You can imagine a world in which we understand these mechanisms better and, you know, the gut flora in really precise terms, and we find a way to shut down that mechanism that's happening with that particular strain of bacteria, or eradicate that strain of bacteria, or introduce some other microbe into the gut that crowds that out or overrides it somehow, and problem solved, right? Like, it sounds like that's possible. I'm sure that's unbelievably simplistic, and, you know, it doesn't take into consideration a million factors, but, you know, that's the future that I'm imagining, where you

• 1:12:24Rich Roll?

  have these very precise interventions that are very specific to one thing, that almost aren't interventions at all. You're just introducing something natural into your gut microbiome, and it sets in motion a series of events that rectify that dysfunction.

• 1:12:44Speaker 01

  I entirely agree, and I think, you know, the strategies to accomplish what you're proposing, some of which is already being done, right? But the strategies are already being built. So you may be familiar with the fact that, you know, the current go-to microbiome-based therapy is a fecal transplant, right? So a wholesale transfer of one person's microbiota into another, healthy to a disease, for example, right? There's probably been 50,000 fecal transplants done in clinical settings, you know, safety records impeccable, right? You know, my view is, the fecal transplants are the go-to therapy because we don't know what about the microbiome is therapeutic.

• 1:13:28Speaker 01

  So what you're talking about is more research, getting to the point where there are specific organisms with defined properties, that you can say, all right, this is an organism that's potentially therapeutic, and then matching it to an individual who may be receptive to the beneficial effects of that particular organism, what we in science call personalized medicine, right? I do believe this is the future, and I do believe that once we have more research, and we know what are the particular ingredients in a fecal transplant that may Be, you know, that therapeutic, uh, uh, you know, effect, right? But the reason why I'm just really excited about this, in addition to the fact that this is what I do, but is the fact that, again, I wholeheartedly believe that the vast majority of human disorders where the microbiome has evolved, involve the person's genetics, involve a genetic predisposition,

• 1:14:13Speaker 01

  like a vulnerability coupled with a microbiome vulnerability, right? And as we sit here today in 2024, it's still very, very hard to correct a person's genetics, right? But we certainly can change our microbiome. We can introduce particular organisms, we can get rid of their entire community and put in a new community. So if there are two levers to pull, as you know, today, we can pull the microbiome lever. We still can't pull that genetic lever, lever, right? And so, again, if a person has, you know, genetic predisposition, their microbiome is not healthy, they have disease. If we make their microbiome healthy, maybe it overcomes or compensates for that genetic predisposition.

• 1:14:48Rich Roll?

  You find the healthy donor or the super donor and you collect their sample, or whatever you call it, and you ship that to the very tony fecal transplant clinic, where you recline in, in, you know, a nice chair and you're given a nice tea or something. And, and I, you take these in capsule form, I suppose.

• 1:15:11Speaker 01

  Mostly capsule, but then there's enema and

• 1:15:13Rich Roll?

  There's enema, right?

• 1:15:14Speaker 01

  And an NG tube, maybe it's a gastro.

• 1:15:15Rich Roll?

  But there's a, is it, is there not a colonization problem? Like, would you have to, like, it's not a one treatment thing, right? Like, what does it take for this new population to take hold and make a difference?

• 1:15:28Speaker 01

  Context-specific, and again, largely unknown, we're at the cutting edge, right, of research. Context-specific, meaning that if it's an acute gastrointestinal infection, right? That one treatment seems to, seems to solve the problem, right? But again, that's like, when I have a bacteria growing in my intestines, that's making me very, very sick, causing, you know, stomach pains, bloody diarrhea, like loss of, you know, weight, lethargy, right? It's called a cluster defecile infection. It's quite prominent, I think 30, 40,000 people a year will get this and, and, you know, it can be fatal, right? In those cases, fecal transplants have a 93% effectiveness rate.

• 1:16:09Rich Roll?

  Wow.

• 1:16:10Speaker 01

  Better than any FDA-approved drug for C. diff, classroom difficile infection. So in that particular, in that case, you know, one treatment is enough. We know this, this is a fact, right? Because essentially you're putting out a fire, right? But in more chronic disorders, what we've been talking about for the, for the past few minutes, you know, neurological disorders, inflammatory, you know, think about allergies, think about autoimmune, like multiple sclerosis or rheumatoid arthritis, where these are lifelong conditions. It's still unknown how many treatments a person needs to have.

• 1:16:38Rich Roll?

  Mm-hmm.

• 1:16:39Speaker 01

  I, I, I think, again, there's exceedingly little data, so I'm speculating, but I don't think one treatment is going to be effective. My rationale for that is that, again, your lifestyle, your genetics reshape your microbiome. So I can, you know, I have an autoimmune disease, right? So if my microbiome were cleared out and a healthy microbiome were put in, and maybe my symptoms went away. I believe sooner or later, my lifestyle, my genetics are going to reshape that healthy microbiome back into something that's pathogenic, something that's not healthy anymore, right? So I do think that, that, you know, I guess that, that long-term, you're going to need resupplementation, right? But, um, not different than taking a pill a day, right? Maybe even easier, right? Or an injection, you know, every couple of weeks or so, right?

• 1:17:24Speaker 01

  And so, again, these are chronic disorders, I believe have to be managed with chronic therapies in most cases.

• 1:17:31Rich Roll?

  It also stands to reason that this might be a field where AI could be helpful because you're dealing with just so much data and just, you know, a numerable number of strains and different types of microorganisms. And, you know, I don't know that our brains have the capacity to understand the complexity of how all of these things are interacting with each other to determine what's causing what, what's correlative, and what is something that we need not pay attention to. But if you could apply some kind of superintelligence to study the interactions between all of these things, it seems like that could be a helpful diagnostic.

• 1:18:08Speaker 01

  Yeah, it's happening in, in, in real time as we speak because, again, the ability to generate microbiome data is, is accessible to most clinicians and most scientists, right? So, you know, I can have my microbiome secret within. Literally, within a couple of days, I mean, I have access to the technology. I can know what's exactly in my microbiome and really generate large data sets. And we can go even beyond just a microbiome. So, you know, oftentimes, we want to know not just who's there, which is what microbiome analysis tells you, because again, you're sequencing DNA. So it tells you the organisms that are there. We like to know what they're making, like what are the molecules they're producing. So you can look at RNA, which is made from DNA, which is one step closer to understanding what are the products of the microbiome.

• 1:18:52Speaker 01

  And then, you know, a more recent technology that's been layered on to microbiome analysis is metabolomics, to look at what are the molecules, the really, the business end of the microbiome. So you generate all of these data sets, right? But what happens is, again, this is how science unfortunately works, is there are a lot of piecemeal studies, like self-contained studies, where I can have even thousands of people in a study, right? But I can report the data set in one study, and it's very, very hard to know, because of both methodological differences and, you know, and, you know, the results, how much this study correlates with another study, right? Again, all this is done manually, right?

• 1:19:32Speaker 01

  I think, I think the microbiome space, you know, at large, is a really good, you know, playground, if you will, for, for AI, because we're generating massive data sets across a number of different conditions. I think it's hard for people to see those patterns, but, you know, I know a number of groups that are, that have already made really nice breakthroughs, taking publicly available data, data that's generated even, you know, sometimes years ago, and seeing things that were just not obvious.

• 1:20:00Rich Roll?

  Right, right, right, right. Yeah, I had Tim Spector in here, and he was sharing about the Zoe app, and that allows for kind of this mass experiment where they're just collecting so much data on people and their lifestyle habits and their genetics, genetics, et cetera. And his, you know, he has this hope that, you know, from that, they're going to be able to divine, you know, kind of hidden truths around how the microbiome is operating and contributing or not to certain conditions.

• 1:20:30Speaker 01

  Yeah, I think it's the future. I mean, the present and the future.

• 1:20:34Rich Roll?

  What is the, what are, what are some of the studies that are underway right now that have you excited or what is the, like, what is the ultimate study? Like, if you could design the perfect study to help resolve some of these questions that you have that would enlighten us, what would that look like?

• 1:20:49Speaker 01

  I would test the, the concept of causality, right? To what degree are changes in the microbiome contributing or even causal to some of the diseases that we're talking about, right? And I think this is virtually impossible in diseases of aging or even, even like autoimmune diseases, which tend to manifest in, you know, adolescence or, or early adulthood, right? Because so much has happened in our lives, so much information, data was lost because we weren't tracking people, their diet, their exposures from infancy. And so the, the dream experiment that I would do is either in autism or in type 1 diabetes, where the diagnosis is very early in life, within the first five years, right? And so

• 1:21:34Speaker 01

  I, and I would, I've, I've implored large funding agencies to do these types of studies, where you follow at-risk pregnancies, right? So a person, a family with a child with autism, the next pregnancy is highly at risk for, for developing autism, right? And so, and same with, with autoimmune disease like type 1 diabetes. So you follow the pregnancy, so you collect as much data from molecular data from the mother as possible, as well as metadata, like, you know, did they get sick, what were their diets, so on and so forth, right? But you actually are looking at the microbiome, looking at their blood and metabolome. And then now track that infant over time, right? From birth through the first several years, how did they, what is the development of the microbiome? What

• 1:22:17Speaker 01

  was their immune profile, you know, throughout this? What were their sort of neurological endpoints, in addition to, you know, behavioral data, in addition to, to symptomology, right? And some portion of those individuals are going to develop the disease and some portion are not, right? But now you have this rich data going back to the beginning, to the in utero development, right? So again, you're capturing all that historical data, which is hard to do when you get a Person diagnosed with a disease at the age of twenty or later. So to me, that's like the dream experiment. We do, again, we do this. It's FASA. We do this in mice all the time. You know, these are the studies that I think we need to do in people.

• 1:22:56Rich Roll?

  Right.

• 1:22:56Speaker 01

  And that really gives us, you know, I think, you know, both that that longitudinal, you know, what happens before what? Type of data, but also now insights, potentially windows into when and how to intervene. Right? So if if one hypothesis is that a child with autism versus a child with autism, that's somewhere along the way. Their microbiomes diverged, you know, the autistic population, they went in a different direction. Right? If we knew when and where that direction was, maybe we can steer them back towards what's healthy. Again, a hypothesis.

• 1:23:29Rich Roll?

  Mm hmm. And allow you to figure out what are the variables that you don't need to worry about versus the ones that are the most important? Yeah.

• 1:23:38Speaker 01

  That's right. That's right. And again, our ability to not just capture a lot of data, which is not just molecular data, but you know, you're using wearables, using like, you know, there are people developing camera systems and software to track behaviors inside a person's home. Right? To know like, you know, what types of behaviors are they exhibiting? Right? So just marry that rich data with the molecular data. And again, you know, the two problems that have really faced us are data storage. When you collect that much data, like where do you actually put terabytes of data, right? And that problem is solved or solvable. And then the AI portion that we can now go back in and analyze just large, large, large multimodal data sets.

• 1:24:22Speaker 01

  It's not just like large data sets of molecules, but molecules and behaviors and immune profiles and, you know, who they talked to. And, you know, did that person have an infection when they met with them? I mean, just think about like how complex and rich that data is. We can actually start mining that down.

• 1:24:38Rich Roll?

  Yeah. There might be some privacy concerns with a little bit of that. It's sort of a voluntary surveillance state in order to do that. But we are signing up for that world where, you know, I got wearables and, and, you know, I'm tracking all, all different kinds of things. And those tools are only getting better and better and better. And the diagnostics, you know, that go along with it are getting better. So I think it is an exciting time and it feels like it's accelerating really quickly.

• 1:25:04Speaker 01

  Yeah. Yeah. I mean, the privacy issue is a significant one.

• 1:25:10Speaker 01

  I feel like we've given away a lot of privacy.

• 1:25:12Rich Roll?

  Yeah.

• 1:25:12Speaker 01

  You know, over the last several years, right? I mean, just think about how much information is available on our cell phones and who has access to it.

• 1:25:18Rich Roll?

  Who do you think is listening on that thing right now?

• 1:25:20Speaker 01

  I get solicited for maybe, I get solicited for advertisements. I mean, this has happened more than once, maybe I'm sure it's happened to you or your listeners as well, right? Where I mentioned something I haven't talked about in years and all of a sudden there's an ad popping up on my newsfeed.

• 1:25:34Rich Roll?

  All the time.

• 1:25:35Speaker 01

  I mean, this is not a coincidence.

• 1:25:36Rich Roll?

  I know. Scary. Let's talk about cravings and appetite because this is just mind blowing stuff. What do we know and not know about how the gut microbiome is influencing the foods that we crave?

• 1:25:52Speaker 01

  An area we've worked on a little bit, you know, very recently, we have active projects in this. So I'll take one step back. In terms of food craving, some of the initial work came from obesity studies, right? And so historical data in mice, some human data as well, that the microbiome, and I think it's, you know, I'd say it's, it's pretty solid these days in terms of evidence, that the microbiome is involved in obesity, right? And the original hypotheses were, and I think rightly so, is that this was a metabolic influence, meaning that, you know, microbiomes extracted more or less calories from food or had different molecular byproducts that were resulting in obesity.

• 1:26:38Speaker 01

  And that certainly is happening, right? But what was an offshoot, and I think quite unexpected for the researchers who did this work, was that when you changed a person's microbiome while you were studying obesity, you're actually changing their feeding behaviors as well, right? Their appetite was changing and, you know, their food preferences were changing. And so this emerging concept that again was a byproduct of the original hypotheses, that changing a person's microbiome changed their behavior, right? And so what we, and dovetailing on all of that work, what we've shown recently is that a mouse's microbiome affects their desire to eat palatable foods or hedonic feeding, if you will. Sugar, right, is one example of high-fat foods, right? And it's pretty interesting, the data.

• 1:27:23Speaker 01

  And so we published this last year, another group published this after us, and so we feel better about our data as well when it's validated, is that when you remove a mouse's microbiome, it actually desires more of these hedonic foods, of these palatable foods. It doesn't eat more of its chow, it just eats more sugar when you present that than a mouse that has a complex microbiota, right? So something about an animal's microbiome is suppressing their desire for sweets or junk food, if you will, right? And so, again, broad-sweeping, you know, changes, but again, linking the microbiome to this behavioral effect. So, in fact, in the studies, the way we do is say, we don't see obesity, we don't see

• 1:28:08Speaker 01

  metabolic changes, we're just seeing feeding change, we're just looking at the first few hours, you know, after changing an animal's microbiome.

• 1:28:14Rich Roll?

  Well, not just the feeding changes, but also the energy that the mouse is willing to expend to get the sugar, right? Isn't that an added kind of wrinkle to the whole thing? The intensity of...

• 1:28:26Speaker 01

  We haven't exclusively ruled out the energetic component, because it's sugar, but we've done enough, you know, we've done experiments like sucralose, right, where there's no calories, right?

• 1:28:36Rich Roll?

  No, I mean, energy in terms of like, the motivation of the mouse. Like, they have to press this button, and you're able to calculate, like, they're going for it. Like, they're gonna keep pushing that button, like, they're willing to go out of their way, as a measure, I guess, of the intensity of the craving.

• 1:28:53Speaker 01

  That's exactly right. So the word is motivation, right? So how motivated is the animal? How hard is it willing to work for that sugary treat, right? That behavior is modulated by the microbiome.

• 1:29:03Rich Roll?

  That's fucking crazy.

• 1:29:05Speaker 01

  Yeah, it is. And we've recently identified a set of, again, these are mouse species, they're not, you know, these same organisms do not exist in people, a handful of organisms that are mediating this effect. And so we're at the stage where we know, at least we have candidate organisms, and so now we want to know, how is that signal being sent to the brain? How are these organisms actually telling a mouse that it, you know, craves more sugary treats? than a mouse that doesn't have those organisms. Right. And so I think, once we unlock that biology, and it may be novel biology, it may be, you know, other systems that were already known, but just didn't, we didn't know that the microbiome was accessing those systems. Once we know that, then it allows us to intervene. Right. And then there's, you know, and so you're asking about feeding and, you know,

• 1:29:48Speaker 01

  but I think what's interesting and maybe just extrapolating further is a lot of the circuits, the neural circuits involved in feeding are involved in, you know, you know, other hedonic behaviors, like alcohol abuse, gambling, smoking. Right. And so I think there's, you know, the potential that this research will allow us to think about something broader than just feeding, but maybe think about addiction and, you know, sort of other, you know, learned behaviors, you know, maybe negative behaviors that we may be able to intervene in. In a, you know, as we're talking about in a very natural way.

• 1:30:22Rich Roll?

  Yeah, it's very exciting. The idea that you could modulate cravings by altering the microbiome in some way is fascinating and just the idea that, you know, we're not necessarily as in control of our thoughts as we may believe. I want to touch on sentience in a minute, but I also wanted to share like what might be the dumbest idea ever and just tell me if this is ridiculous, but in the most simplistic terms, is there any truth to the idea that, you know, on this adage of like you are what you eat, like if you just eat McDonald's all day long over a long period of time, you're, you're seeding your microbiome with biota that is in that food. And on some level, perhaps

• 1:31:07Rich Roll?

  creating a new colony of gut flora there. Is there any evidence to suggest that that in turn could create a cycle of craving for that food? Because those microbes want more of that McDonald's food because that's what they like, that's what they are, that's what they need more of. Which is why when you try to quit fast food or some analog of that, you have intense cravings that only subside over time and can be supplanted when you start eating healthy food. And then all those healthy foods that you thought you hated, suddenly you have a taste for and you. You, maybe the cravings aren't as intense, but like you do look forward to them because

• 1:31:49Rich Roll?

  you are seeding your gut flora with something new and healthier for you.

• 1:31:54Speaker 01

  Yeah, I don't know of any ever, it's an interesting hypothesis.

• 1:31:57Rich Roll?

  I mean, that's like my kind of like layperson's, you know, operating theory.

• 1:32:01Speaker 01

  Yeah, and you seem to be a believer in the microbiome, right?

• 1:32:05Rich Roll?

  I definitely, I definitely believe in that. And I know like my idea is like as rudimentary and as perhaps as dumb as possible, but like is, do you think that there's, could be any truth in that?

• 1:32:15Speaker 01

  I've learned to not exclude any hypotheses that involve the microbiome.

• 1:32:21Rich Roll?

  Could I go to Caltech and study this with you?

• 1:32:24Speaker 01

  I think the experiment would be actually quite straightforward in my, because again, we can feed them whatever we want and then measure their cravings and really rigorous and accurate, you know, mathematically accurate ways.

• 1:32:37Speaker 01

  I don't know of any evidence for or against this hypothesis, so it's testable. If it were, you know, first of all, and I think it'd be in just a subset of people, right? I mean, just like any other vulnerability, some of us are just more or less, you know, prone to repetitive or addictive behaviors, right? Whether or not eating a particular food makes you desire that type of food more, you know, and if that process is mediated by the microbiome, I would say it's completely, again, I don't see any literature, but I can see other, other ways to explain that, right? It could just be entirely behavioral and neuronal, right? Meaning that, you know, our circuits are being...

• 1:33:20Rich Roll?

  Creating a pathway.

• 1:33:21Speaker 01

  Yeah, and being reinforced, right? So I feel a certain way when I eat, maybe I feel good. I personally do not feel good when I, when I eat fast food, but I think a lot of people would, right? Comfort food and other, other ways to sort of, you know, improve mood. And so the reason why I bring a mood is that, you know, if I eat something or I drink something that makes me feel good, then that's reinforcing a neuronal circuit. And every time I do it, I'm, you know, going to want more of that, right? So I can see entire pathways that have nothing to do with the microbiome. But Rich, you're welcome to our...

• 1:33:51Rich Roll?

  Okay, good.

• 1:33:52Speaker 01

  Anytime.

• 1:33:52Rich Roll?

  I'm gonna visit.

• 1:33:53Speaker 01

  And you can do the work. You will, you may have to take a break from the podcast.

• 1:33:57Rich Roll?

  Can I just tell your students, like, here's what I want?

• 1:33:59Speaker 01

  I don't tell my students what to do.

• 1:34:01Rich Roll?

  Anyway, I'm just kidding. The implication that the microbiome plays this important role in all kinds of metabolic systems and this link with Parkinson's and with autism and perhaps other, you know, neurological disorders and the impact on mood and anxiety and your stress response and cravings and anxiety like begs the question of just how sentient we are. It's an affront to our sense of self and kind of an assault on the ego to understand

• 1:34:44Rich Roll?

  that we're not always at the helm in a very interesting way. Like, we are this scaffold and we're host to trillions of these organisms. And in a certain way, you can make the argument that at times they're in control of things that we delude ourselves, that we're handling ourselves with our own sentient minds.

• 1:35:04Speaker 01

  Yeah, yeah, I think the microbiome is part of the complex, you know, being that we are, right? And they're a component of it. And whether or not they're directly influencing our thoughts or modulating our thought process, right, tuning it up or down or, you know, our, you know, response to an environmental stress, as I mentioned, or, you know, some reward behavior, right? I eat or drink something that makes me feel good. And they're just modulating how good I feel. They're not dictating how good I feel. You know, I would probably be more conservative, even though I've written pieces that suggest that the microbiome is completely in charge.

• 1:35:46Speaker 01

  And I think that was naive of me when I thought that way.

• 1:35:50Rich Roll?

  There is no self.

• 1:35:51Speaker 01

  You know, I think it's a continuum, right? I think we are, we have a... Contribution to that to that effect, right?

• 1:35:58Rich Roll?

  Yeah.

• 1:35:58Speaker 01

  Like whether it's a mood disorder, whether it's a behavior, some other behavioral disorder, whether it's like a disease, right? But I know microbiome environments have a contribution as well, right? Yeah, sort of likened it to the Wizard of Oz, like this big machine, this front that you see, but then behind the curtain is like some microbe just pulling the levers.

• 1:36:19Rich Roll?

  Right, or you know, it's a distributed system, though. There's lots of microbes all over the place that are all jockeying for a say.

• 1:36:26Speaker 01

  That's right. And again, it's going to be different in different people, right? For, you know, whether it's genetics or their lifestyle. But, you know, again, I think, I think at the end of the day, they're a piece of this biology, of this, you know, behavior, these responses, but importantly, a modifiable piece, right? One that we can control even today. We need to get better learning at how to control, you know, our microbiome, make it healthier, for example, or allowing us to, you know, have, you know, overcome mood disorders, for example, right? But again, much easier to do that than to alter our genetics or alter our lifestyle, right? And so I'll give you a really simple example is, you know, there's a huge percentage of

• 1:37:11Speaker 01

  people with diabetes who don't need to take medication, right? Who can just eat a little bit better, have a more active lifestyle and can manage their blood glucose, right?

• 1:37:21Rich Roll?

  Type 2.

• 1:37:22Speaker 01

  Yeah, type 2.

• 1:37:23Rich Roll?

  Or pre, pre-type 2.

• 1:37:24Speaker 01

  We live in a society where I think people like to take pills, right? As opposed to change their lifestyle. So again, I just want to be, you know, I just want to be complete and rigorous about this. There are other levers to pull, like lifestyle. You don't have to change a person's microbiome and certainly very hard change our genetics. But, you know, lifestyle changes are, you know, can be therapeutic as well in a lot of contexts, right? For mood disorders as well. I mean, sleep, exercise really help with mood and affect. And so there are other levers to pull, but I feel like the microbiome again is one of multiple ways that we can intervene in these processes. But, you know, even though I have said this in the past, I don't think in most cases microbiome is causing a human disorder, for example.

• 1:38:07Speaker 01

  I think it's just contributing to it, either positively or negatively.

• 1:38:11Rich Roll?

  What are some other best practices if we want to protect our gut health and make sure that we're not dysregulated in ways that we have some agency over?

• 1:38:21Speaker 01

  I think gut health is linked to health in general, right? And, you know, the four, the four aspects of which, which I suspect you and many of your listeners practice is healthy diet, and we can define that, you know, quite specifically, exercise, getting good sleep, and managing stress. You know, if you do those things, you have a healthy gut, you have a healthy microbiome, you have a healthy body, you know, overall. In terms of what is going to affect your microbiome the most, at least the data that we have today is diet, right? And that's intuitive, right? You know, the microbiome digests the vast majority of the molecules we put in our body, or the food that we eat, right? We essentially live off the byproducts of our microbiome.

• 1:39:05Speaker 01

  So I've seen data that suggests 90% of the actual molecules that we put in our body as food are modified by our microbiomes and then enter our body. Only 10% of the actual molecules in food are what our body actually sees, right? And so, you know, the microbiome is, you know, they have first dibs at what we're eating, and their change, their behavior, their, their structures are changed by our diet. And so in terms of effect, I think the diet's going to have, you know, the largest impact on our microbiome. And a lot of, a lot of data suggesting that particular types of diet, you know, plant-based diets, and really diverse foods, you know, correlate with a healthy microbiome and a healthy, healthy body.

• 1:39:45Rich Roll?

  The wider the diversity of plant foods and the more fiber-rich those foods are, the better off you're going to be, by and large, yes?

• 1:39:53Speaker 01

  Our body is, is quite good at digesting protein, quite good at digesting fat, but we've essentially outsourced the ability to digest fiber to our microbiomes. And there's, you know... Very good reasons for that, right? You know, it's not to get in the weeds too much, but the chemical bonds of protein are pretty, proteins are pretty simple. And we have, you know, enzymes like trips and chemotrips that can break down those bonds. Similar to fat, we can digest a lot of our fats with enzymes that we have in our own genomes, right? So essentially like take fat and protein, break it down into its molecular components, its pieces, and then our body uses that for fuel and energy. But for carbohydrates, the chemistry is so complex that we would need so many enzymes

• 1:40:38Speaker 01

  to break down all the different types of fiber that we eat, that our genomes would have to be much larger than they currently are, right? And so again, that's why I say we've outsourced that to our microbiomes, because the vast majority of carbohydrate degrading enzymes are not in our own genomes, but are in the genomes of our gut bacteria, right? So really, the fiber helps. And again, the data to suggest that a diverse fiber-rich diet correlates with a healthy microbiome is quite robust, right? So again, there's thousands of studies where people have taken microbiomes, largely from feces, so, you know, it's easy to get stool samples, looked at people's microbiomes. And in the majority of those cases, the diseased population has a less diverse microbiome than the healthy population.

• 1:41:22Speaker 01

  So the more organisms you have correlate, microorganisms have correlate with health, right? So that's one piece of data. The other piece of data is that people who eat plant-based diets and diverse plant-based diets have more complex microbiomes. So if you put those two things together, complex diet leads to complex microbiome which associates with health.

• 1:41:43Rich Roll?

  What about fermented foods?

• 1:41:46Speaker 01

  Not an area that I'm terribly familiar with, but I'm a little bit more skeptical. I would put that, again, in my personal mind, I would put that in the same category as probiotics. Again, these are large organisms that don't come from humans that are in fermented foods, so they're likely not evolved to network with our bodies in ways that microbes from our own body, you know, that originate in our own bodies or live exclusively in our own bodies. Doesn't mean that they have no effect. It doesn't mean, maybe they even have in certain people, you know, pretty potent effects. But I'm in the camp of Human-evolved organisms likely being the area that, you know, the, you know, aspects that we should look at in terms of the microbiome that we can leverage.

• 1:42:29Speaker 01

  So, small effect sizes may not give us the therapeutic effects that we're looking for. We need something more potent. And I just surmise that the organisms in our body are going to be more potent.

• 1:42:41Rich Roll?

  If somebody's listening to this and they're like, "Sure, I can increase the amount of fiber in my diet, I can increase the plant diversity, but I have no idea if my gut microbiome is adequately diverse." Is there a test? Like, how can one determine the current state of affairs?

• 1:43:01Speaker 01

  I was reading an article just a couple of days ago that there are 170 companies that will analyze your microbiome for you for a fee, right? And again, I think that, based on the technology, they're probably going to, and I don't know the vast majority of these companies, you know, I suspect that the majority of them will do a pretty good job in analyzing your microbiome. In terms of interpreting that data and giving you actionable outcomes, there I'm quite skeptical. I don't think the field is at the point where we can say, you know, you, you know, based on your microbiome, if you eat this food, or you take this probiotic, you're going to shift your microbiome from an unhealthy state to a healthy state.

• 1:43:43Speaker 01

  I think, you know, we need a lot more data to get to that point. So, the profiling, the cataloging, I think we're going to do a good job at, I'm not sure that the outcomes that we're looking for would be, you know, would come from these microbiome-based studies, right? Doesn't mean people shouldn't do them, but I would say, take it all with a grain of salt, right? And, you know, it's maybe a rough benchmark for, for health, right? Again, you're, you're looking for very obvious things. So, for example, if you get your microbiome sequence, I think maybe this is a good, a good use of microbiome profiling. If you get your microbiome sequence and you have a large amount, proportional amount of an organism that's clearly bad for you, right? Then maybe you should do something about your microbiome, right?

• 1:44:28Speaker 01

  I think the vast majority of cases, you're going to look at microbiome profile and you're going to say... I'm not sure exactly what this means.

• 1:44:34Rich Roll?

  Right, like, how am I supposed to interpret that? But I suspect it won't be long before you can marry the results of your genetic testing with the results of testing your microbiome and get a better understanding of, well, I have this, I'm high risk for this, and I'm seeing an elevated level of this over here in my gut, and that's an indication that I need to, you know, rectify something.

• 1:45:01Speaker 01

  I hope so.

• 1:45:02Rich Roll?

  Yeah.

• 1:45:02Speaker 01

  Right, you know, based on our conversation.

• 1:45:04Rich Roll?

  How far away are, like, so you, speaking of businesses, I mean, you have a couple companies that you founded that are working on these problems and creating therapies, therapeutics, interventions. Paint the picture of five years from now, and perhaps even like the utopia that you're aiming for. Like, what does the world look like if we have the breakthroughs that you can reasonably anticipate us having in the upcoming years? And what would that look like in terms of how it changes healthcare and the practice of medicine? And, you know, personally, how we live our lives?

• 1:45:41Speaker 01

  Yeah, I think that maybe two lines of thinking, though, in theory, you know, the sky's the limit, right? But two lines of thinking is, if we are able to identify, as you were just alluding to a second ago, you know, gene-environment interactions, like how our personal genetics interact with our personal microbiomes, we may get pretty good at preventing certain diseases. I'm not sure we can treat or reverse many diseases. I hope so, you know, and I wouldn't exclude that possibility. But I think it's a lower bar, a more reasonable goal, if you will, to say, I'm at, you know, I set my sample to 23 and me, I'm at risk for type 2 diabetes.

• 1:46:25Speaker 01

  Is there something I can do microbiome-wise, but also health-wise, as we talked about, to prevent that day where actually my blood glucose goes above a certain threshold where I'm diagnosed with diabetes? Right, so I think the preventative aspect is the way to go. But I think that the other axis to think about is just the psychological part is that when people are taking something that they feel is natural, that they, you know, believe is going to make them healthier, then that might prompt them to live healthier lifestyles. So it's a sort of a cascading event. I think you probably know a lot about this, and this is certainly, I speak in personal experience as well, right, is that, you know, it's like exercise. Like, once you exercise and you see some benefits, you're more likely to eat better, right? And so I think that, you know, the microbiome offers

• 1:47:08Speaker 01

  that, that, that window, if you will, or that opportunity to begin a healthier lifestyle. And again, it did for me.

• 1:47:14Rich Roll?

  You shared that the FDA has really become an ally. Is there a sense that the conventional medical establishment is coming around as well and is supportive and receptive to the work that you're doing and your colleagues are doing?

• 1:47:31Speaker 01

  They are, but they're, you know, from a big pharma perspective, right? So again, thinking about who's really going to develop these drugs, right? You know, I don't think big pharma has yet sold on the microbiome, and I think there's some very good reasons for that. And so it's going to be smaller companies. It's going to be, you know, maybe even health food companies, not traditional pharmaceutical companies that are going to make the biggest breakthroughs. And again, I don't think regulatory issues are going to stand in the way. I don't think manufacturing is going to stand in the way. And certainly not societal acceptance. I think society is, would welcome these types of natural approaches. But for them to become more mainstream, which is not exactly what you asked, but maybe thinking about, like, you know, forward looking, you know, to what degree is this, is the

• 1:48:16Speaker 01

  microbiome being leveraged to actually treat disease? There's going to have to be buy-in from the, from the big pharmaceutical companies. And I suspect, I don't know, and there's not one answer, but I suspect they will take a conservative approach over time. And until there is For better or for worse, a revenue stream that is attractive to them, they're probably not going to jump in. Yeah, yeah, yeah. And so, and again, I think there's some, beyond, not to be too cynical, right? Beyond just the financial component, there's some, you know, really structural reasons why Big Pharma isn't completely sold on the microbiome. For example, is there's no precedent for an organism that, for a therapeutic that's alive, that's a living drug, right?

• 1:49:01Speaker 01

  And so pharmaceutical companies don't even know how to wrap their minds around it, let alone a business plan, right? For example, is you may know that most pharmaceutical companies are not developing new antibiotics, right? Even though antibiotic resistant bacterial infections are a huge problem and a growing problem, right? The reason for this, and about, it started about 20, 25 years ago, that pharmaceutical companies just started shutting down their microbial genetics division or the antibiotics division, is because, you know, infectious disease are one of the few things that modern medicine can actually cure, right? And by curing, again, I'm going to be cynical, by curing. I know where this is going, but go ahead. They've lost customers, right?

• 1:49:43Speaker 01

  You know, so they want to treat chronic disorders, they don't want to cure anything, right? And so one business model is, well, you know, and there's some recent precedent for this that I'll touch on in a minute, is, you know, is the drug something, let's say it's a live organism, is it something you're going to have to take every day and you're going to have to keep buying capsules? Or if you take it one time, is it going to colonize, right? And give you lifelong or many, many months or years of benefit? The one time hit, not interested. Yeah, you know, and I don't know. So, so there have been, you know, breakthroughs in genetic medicine recently, where it is one injection, one treatment that solves a genetic problem.

• 1:50:23Speaker 01

  These are like highly penetrant, where you know the gene mutation is causing, there's very little environmental contribution. Again, this is the very small percentage of human disease is like monogenetic, highly penetrant genetically caused diseases, right? And so there are some therapies that have come out, you know, in the past few years, you know, they're like tens of thousands, hundreds of thousands of dollars for one treatment, right? And so maybe over time, there'll be more of a business model for the microbiome. But again, that's like, that's one of, by multiple reasons why Big Pharma is still not interested. Sure, sure. But will, will they be and when they will be? I don't know, I can't speculate, but you know, I think if. The customers are there and the effects are there and the benefits are there. You know, that's an opportunity.

• 1:51:08Rich Roll?

  Yeah, I'm a former lawyer, so I can't help but think about the intellectual property. Like, can you protect, you know, a strain of a microbe strain such that it would be something that a larger company would feel comfortable making a giant investment in?

• 1:51:28Speaker 01

  Yeah, the current way to do it, which may not be the best way to do it, is to genetically modify that organism, is to make sure that it's doing something that wasn't happening in nature, right? You may know this from your, I know you're a recovering lawyer, but I think it's called like 101 or something, right? Is it a natural product? And so the dogma has been that if it's, if something occurs in nature, then no one can own it. There have been some end arounds, you know, legal end arounds on that as well. And so, but the vast majority of cases, you know, if, you know, you have a microbe, I need that microbe, you know, a drug company cannot patent the microbe that they're giving to me. So the approaches that they're taking are essentially formulations, methods of use, right?

• 1:52:11Speaker 01

  And in some cases genetically modified organisms that have a property that they can protect.

• 1:52:17Rich Roll?

  As soon as you start to genetically modify it, though, it feels less like a natural intervention and more like a drug.

• 1:52:25Speaker 01

  It does.

• 1:52:26Rich Roll?

  Or more like a Monsanto seed or something like that.

• 1:52:28Speaker 01

  It does, it does. And then you open up the regulatory problems, right? Is because, you know, regulators are bullish on the microbiome because it's natural. Once you start making it not natural, then you're gonna have to satisfy it. And again, there's, there are paths for that as well, right? And so I think that's, that's one strategy. But again, for a drug company to do what you just suggested, and there are some really interesting candidates, right? So there's some disorders where you can just take a microbe and just have it make more of what it was making, and that would be therapeutic, right? You know, for drug companies to do that, I mean, the investment is so heavy, the upfront investment is so heavy before they see the return that, again, they're just not doing that, at least not at scale, like not in a large scale at this point. And there have been a number of pharmaceutical companies, you know, smaller.

• 1:53:12Speaker 01

  Biotech companies as well that have taken not pharmaceutical, small biotech companies that have taken this approach. By and large, they just haven't done well.

• 1:53:20Rich Roll?

  Mm hmm.

• 1:53:20Speaker 01

  Um, meaning having genetically modified microbes as therapeutics.

• 1:53:26Speaker 01

  It's a case by case basis. In some cases, they probably made bad decisions, but overall, my view of that entire area is that is probably too, you know, ahead of its time, right? There wasn't enough of a sort of a receptive audience from pharma, if you will, for those for those drugs to to find a home ultimately. So again, I think people will just keep knocking on those doors and and hopefully, you know, we'll learn along the way of like, what are the organisms? What do we need to do to those organisms to get the the IP protection? Because that's going to be important. Again, if you think from a business standpoint is any company, whatever the product is, right? If they can't own it, then they can't monetize it in a way that they'd like.

• 1:54:03Rich Roll?

  There's no, there's no economic incentive. Yeah.

• 1:54:06Speaker 01

  So it's all goes together.

• 1:54:07Rich Roll?

  Right. So with the two companies that you have, you have Axial and then symbiotica. What's the other one called?

• 1:54:14Speaker 01

  The other one's called Nuanced Health.

• 1:54:15Rich Roll?

  Nuanced Health. I don't know why I thought. Anyway.

• 1:54:18Speaker 01

  I I used to have a company called symbiotics many years ago.

• 1:54:20Rich Roll?

  That's what I was thinking of. Okay. So what are what are what are those ventures looking at? What are they focused on?

• 1:54:28Speaker 01

  Sure. So Axial is a clinical stage company, meaning that they've already taken drugs into clinical trials. And they're essentially a gut-brain company. And so their, you know, programs are in autism and in Parkinson's. And their approach is is actually quite interesting. And again, a lot of this is, you know, technology that originally came from our laboratories or academic research that then the company translated into into medicines. And the approach they've taken is to essentially not try to develop drugs that come from the microbiome, but identify pathways in the microbiome that if you can drug with a small molecule, you'll get benefits, right? And I've already, we've already talked about two of the examples, right?

• 1:55:12Speaker 01

  So one is for EPS. So for EPS is being made by a dysregulated microbiome. It's making more for EPS than it should. So both of us have 40, everyone has 40PS in their bloodstream and the microbiome. Makes it, right? But some people are just making orders of magnitude more and we feel like that's tipping the balance towards disease. And so what Axial has developed is a drug that essentially sequesters or binds for EPS as it's traveling through the gastrointestinal tract. Bacteria make the molecule, the drug binds it, sequesters it, and then, sorry to all, we just poop it out, right?

• 1:55:43Rich Roll?

  Yeah, it just becomes neutered.

• 1:55:45Speaker 01

  That's right. Yeah, and just lowers the concentration and gets it back to a more sort of homeostatic or healthy level, right? And shows efficacy in early human studies, but also, you know, a lot of mouse work as well.

• 1:55:57Rich Roll?

  Wow.

• 1:55:58Speaker 01

  And so again, the approach is to use drugs to drug the microbiome, but not use bacteria or fecal transplants or microbial molecules. And the other is in the Parkinson's space. Again, I alluded to this earlier, is that, again, in some percentage of Parkinson's, maybe somewhere around 20%, there's this microbial, there's bacteria that makes a microbial molecule, which leads to alpha-synucin aggregation. They develop a drug to inhibit this process. And again, the drug is only found, it's only retained in the gut. It does not enter the circulation. It certainly doesn't go to the brain. So we know its mechanism of action is in the gut. And so the company took this route of developing these types of therapeutics for two reasons. The first is, if a drug doesn't

• 1:56:43Speaker 01

  enter the circulation, it's much less likely to have side effects, right? And so, you know, the safety, you know, safety profiles on the drugs they develop are exquisite. But the other is thinking about, about pharma is, you know, pharma is more likely to invest in small molecule drugs, the types of drugs that Axial is making than they are in fecal transplants or live biologics, as we just talked about. And so we feel like those drugs are just more transactable. Those assets are just more transactable because now you're speaking pharma's language, right? Small molecules that can be manufactured, you know, quality controlled, batch to batch variation, and you own the actual molecule. You own the actual drug, right? And so that's, that's Axial's

• 1:57:28Speaker 01

  approach. It's essentially try to understand how microbes are talking from the brain to the gut, and then intervene in that process as therapies.

• 1:57:36Rich Roll?

  How far along are you, particularly with the Parkinson's intervention? Like, I'm imagining somebody listening to this who's in the early stages or perhaps is at risk. Are there experimental trials? Is that on the horizon?

• 1:57:52Speaker 01

  On the horizon, but the first trials will be small and they'll probably be first in human studies, meaning that we're, you know, and this is still undetermined because we need to to discuss what the trial looks like with the FDA, but they may likely go into just healthy volunteers, which is pretty standard for for drug development. You oftentimes don't want to go into a diseased population in the first trial because they're just more vulnerable and you're more likely to see adverse events. But in some cases, the FDA allows the first trial to be in a patient population because they either because of combination, they feel it's safe and that there's a medical need. Like, for example, in cancer, you can take a lot of experimental drugs into cancer these days, especially

• 1:58:35Speaker 01

  in people who failed all the the standard of care drugs. And so to answer your question, I can't give a definitive date, but based on historical timelines of drug development, if all goes well, we're probably looking at approvals more than five years from now, you know, probably closer eight to 10 years from now, where there's an actual drug that some population, some percentage of Parkinson's patients can actually take and be prescribed and may help their symptoms. And the other, you know, aspect is that though our goal with the Parkinson's program is to improve motor symptoms, which is classic Parkinson's, as I mentioned, you know, the gastrointestinal symptoms, like the constipation can be quite

• 1:59:20Speaker 01

  debilitating and really affect quality of life. And so if we just see improvements in the constipation, then I think we're helping people, you know, just on that scale as well, right? Because again, laxatives and the in any current medicines just don't work for the for the GI symptoms associated with Parkinson's. And so a lower bar, I think, but hopefully one that will help people. But again, our goal, and with the motto of reaching for the stars, is to is to really improve, maybe not reverse, but slow down, maybe halt the progression of of motor symptoms, like the classical symptoms of Parkinson's.

• 1:59:55Rich Roll?

  Right. Yeah, we had a guy here yesterday called Phil Stutz, who's a, he's a psychiatrist and he's had, he's in his 70s now, but he's had Parkinson's since he was, I think he was diagnosed when he was 21. His palsy is pretty, is pretty pronounced. He's lived with it for a very long time. So we, you know, we did a pocket, he's, you know, it's.

• 2:00:19Rich Roll?

  You know, it's such a debilitating disorder. You know, it's just interesting that you came in literally the day after he was here. So Parkinson's is very much on the, on the mind. And it's a, you know, it's a worthy, it's a really, you know, beautiful, worthy investment of, of your brilliance. So thank you for that. I think it's a really good time for a young person to go into microbiology, too. Like, this just seems like a world that's going to continue to develop and, and, and grow. And it's really at the cutting edge of some of the most fascinating stuff that's happening right now in science.

• 2:00:49Speaker 01

  Yeah, I think there's been a renaissance in microbiology last decade or so. And, you know, in my opinion, driven largely by microbiome research and not all the other microbiology that's going on. Because, though again, really a worthwhile cause to think about, you know, infections, infectious disease, which is still a huge problem. Nothing that, I wouldn't say we've solved anything, right? You know, I can maybe that, that's, that's misrepresenting. We, you know, antibiotics have been revolutionary, right? Extended lifespan in a lot of, you know, children, especially, you know, you know, childhood mortality has really, really been, you know, improved in many societies, not all societies certainly. So we have made breakthroughs. But, you know, I think the microbiome offers just a unique opportunity to, you know,

• 2:01:34Speaker 01

  you know, touch on a lot of other aspects of health that go beyond just infection. Right? Which is, you know, all the chronic disorders that we've just talked about.

• 2:01:42Rich Roll?

  If someone listening to this is inspired by what you've just shared and, and is interested in, in learning more about this world, do you have resources, books, like where can that person turn to kind of edify themselves?

• 2:01:56Speaker 01

  A number of books have been written on the topic.

• 2:02:02Speaker 01

  They come to, I won't name any one, just out of respect to my colleagues.

• 2:02:06Rich Roll?

  You're going to get in trouble.

• 2:02:07Speaker 01

  Right, yeah. But, but, you know, obviously searchable and easy to find. But, yeah, no, we live in a world where, you know, accessing information is quite straightforward. You know, it's a, in, in the absence of giving particular resources, what I would say to your audience is to really be mindful of the source. And the type of of information that you're being exposed to. There still is a lot of hype out there, right? And so I think, you know, trying to figure out ways of identifying the most rigorous research, the ones that just make sense, the ones that really don't feel like they're overblown, you know, are probably the best way to start, you know, and to get

• 2:02:48Speaker 01

  that framework, that foundation of knowledge in the microbiome. And I may get in trouble for this one, but I'd be skeptical of anyone selling a product at the stage, right? A microbiome based product. So just to be specific is, you know, we can tell you what treatment or what drug or what diet or probiotic to take if we sequence your microbiome. I would be very skeptical of those of those sources, not resources. But from an educational standpoint, again, I think there's, you know, a wealth of of information out there. People just should filter in their own ways what they believe and what they don't believe.

• 2:03:26Rich Roll?

  I appreciate you coming to talk to me today. That was truly fascinating. I learned a lot and I'm just more excited about this world than I was a couple hours earlier. So thank you.

• 2:03:37Speaker 01

  Thanks for having me, Rich.

• 2:03:38Rich Roll?

  When you make a big breakthrough, come back and share it with me.

• 2:03:41Speaker 01

  I will, I will.

• 2:03:42Rich Roll?

  All right. Appreciate you. Thanks. Peace.

• 2:03:45Speaker 01

  Thanks.

• 2:03:53Rich Roll?

  That's it for today. Thank you for listening. I truly hope you enjoyed the conversation. To learn more about today's guests, including links and resources related to everything discussed today, visit the episode page at richroll.com where you can find the entire podcast archive, as well as podcast merch, my books, Finding Ultra, Voicing Change, and The Plant Power Way, as well as the Plant Power Meal Planner at meals.richroll.com.

• 2:04:24Rich Roll?

  If you'd like to support the podcast, the easiest and most impactful thing you can do is to subscribe to the show on Apple Podcasts, on Spotify, and on YouTube, and leave a review and/or comment. Supporting the sponsors who support the show is also important and appreciated. And sharing the show or your favorite episode with friends or on social media is, of course, awesome and very helpful. And finally, for podcast updates, special offers on books, the meal planner, and other subjects, please subscribe to our newsletter, which you can find on the footer of any page at richroll.com. Today's show was produced and engineered by Jason Camiolo, with additional audio engineering

• 2:05:06Rich Roll?

  by Cale Curtis. The video edition of the podcast was created by Blake Curtis, with assistance by our creative director, Dan Drake. Portraits by Davy Greenberg. Graphic and social media assets courtesy of Daniel Solis. Thank you Georgia Whaley for copywriting and website management. And of course, our theme music was created by Tyler Pyatt, Trapper Pyatt, and Harry Mathis. Appreciate the love, love the support. See you back here soon. Peace. Plants.